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Leveraging electronic health records to develop cardiovascular risk profiles for primary 
prevention with youth living with HIV in multidisciplinary adolescent HIV care settings 
By  
Sitaji Gurung 
Advisor: Christian Grov 
Background: HIV infection has shown to be associated with increased risk for, and earlier 
occurrence of cardiovascular disease (CVD). Emerging evidence suggests that detectable viral 
load (VL) and CD4 ≤ 200 contribute substantially to increased risk of CVD. Cigarette smoking is 
prevalent in at least 40% of those with HIV, and significantly more common compared to the 
general population. As many as 33% of adolescents are overweight, and this excess weight leads 
to lipid abnormalities, and increases in metabolic syndrome. With the newer formulation of 
antiretroviral therapy (ART) agents available as a component of single tablet regimens (STR), it 
is important to examine their impact on lipid abnormalities in youth living with HIV (YLH). The 
cardiovascular risk profile for YLH has yet to be developed. These findings support a 
cardiovascular risk framework incorporating biomarkers, behavioral measures, and ART 
medications as independent factors of a single multivariable CVD risk function among YLH in 
the United States (U.S.).  
Methods: De-identified electronic health records of YLH who received care in 2016 were 
extracted from multidisciplinary adolescent HIV clinics across the United States. Two analytic 
samples were developed based on Cardiac Risk Score1 (n =813) and Cardiac Risk Score2 (n = 
398) to examine the association of HIV biomarkers (VL and CD4 cell count) with cardiovascular 
risk among YLH aged 14-26 (AIM 1). The second analytic sample of 398 was used to examine 
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the association of cigarette smoking and metabolic syndrome with VL (AIM 2) and examine the 
association of STR and detectable VL with lipid abnormalities (AIM 3) among YLH aged 14-26. 
We used descriptive statistics, chi-square, ANOVA and independent t tests to examine the 
independent contributions of biomarkers, behavioral measures, and ART medications on 
cardiovascular risk among YLH in the U.S. We ran a series of multivariable linear regression 
models and tested the hypotheses that detectable VL and CD4 ≤ 200 will be positively associated 
with increased cardiovascular risk among YLH (AIM 1). We then tested the hypotheses that 
smoking and presence of metabolic syndrome will be positively associated with an increased 
odds of having detectable VL by performing multivariable linear regression models (AIM 2). 
Finally, we tested the hypotheses that detectable VL will be positively associated with increased 
risk of having low HDL and high total cholesterol whereas treatment with STR will be positively 
associated with decreased risk of having low HDL and high total cholesterol by performing 
multivariable logistic regression models (AIM 3). 
Results: Detectable VL was significantly associated with increased cardiovascular risk, cigarette 
smoking, and lipid abnormalities (AIMS 1-3); after simultaneously adjusting for demographic 
and clinical covariates. CD4 cell count ≤ 200 was not found to be significantly associated with 
increased cardiovascular risk (AIM 1). Cigarette smoking was associated with increased odds of 
VL non-suppression; however, the presence of components of metabolic syndrome were not 
found to be significantly associated with VL non-suppression after adjusting for demographic 
and clinical covariates (AIM 2). Treatment with single tablet regimen (STR) was associated with 
decreased odds of having low HDL cholesterol and high total cholesterol (AIM 3). 
Conclusions: Overall, this dissertation demonstrates that a relationship exists between detectable 
VL and increased risk of CVD; and it appears that smoking is positively associated with VL non-
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suppression, which then is positively and independently associated with lipid abnormalities 
whereas STR is associated with lipid abnormalities as a protective agent in YLH. The variety of 
biomedical and behavioral factors that make HIV-positive individuals more susceptible to 
developing CVD is compelling evidence to reconfigure how the two ailments are addressed. The 
targeted population YLH carries a lot of interconnected factors that act as a tide in the ocean 
against seeking them, and it requires a multidisciplinary treatment method to increase its 




















I dedicate this dissertation to my late parents, Inspector Kubir Gurung of the Gurkha 
Contingent Singapore Police Force and Mrs. Bishnu Gurung who continue to watch over me 
from the Kingdom of Heaven. My parents taught me early on that there are no shortcuts in life 
but simply, hard work and dedication, and it is the best lesson I have received from them for this 





















As I come to the end of this “road”, I remember the people who have helped towards the 
successful outcome of this dissertation. I would like to thank the Committee Chair, Dr. Christian 
Grov and members of the Committee, Drs. Terry Huang, Jon Rendina and Kit Simpson for their 
dedication, effective and critical feedback, guidance, and special consideration towards the date 
of my defense. I would also like to thank the Principal Investigator of the ATN Scale It Up 
project (U19HD089875), Dr. Sylvie Naar for allowing me to use the ATN 154 Cascade 
Monitoring data. Lastly, I would like to thank Dr. Brett Millar for your assistance with finalizing 
the dissertation chapters.  
  Being a family means you are a part of something wonderful; it means you will love and 
be loved for the rest of your life. For creating a healthy home environment and providing all the 
support and conveniences to deal with life’s challenges, I am forever grateful to my brothers, 
Nir, Sunkaji, Surje and Kamal Gurung, sisters, Raj Kumari and Mina Kumari Gurung, niece, 
Rina Gurung, Esq. and nephew, Arbinda Gurung. I would also like to thank my husband, Kenzy 
Gurung whose love, unwavering support, and limitless encouragement for the past two years has 
enabled me to stay on track and reached a successful outcome. I passed my 2nd exam in 
September 2018, defended my dissertation proposal in January 2019, and am finishing the final 
component of my PhD in November 2019. 
Last but not the least, I remember my late parents, Inspector Kubir Gurung and Mrs. 
Bishnu Gurung. All that I was, am, and hope to be, I owe to them both. I love you and miss you 
both.  
 
Disclosure Statement: I have no conflicts of interests to disclose. 
1 
 
TABLE OF CONTENTS 
List of Figures, Syntaxes, and Tables .................................................................................................... 3 
CHAPTER 1 – INTRODUCTION ............................................................................................................ 4 
Overview .................................................................................................................................................. 4 
Research Theme and Conceptual Basis ................................................................................................ 5 
Public Health Significance ..................................................................................................................... 6 
Specific Aims ......................................................................................................................................... 13 
Methods .................................................................................................................................................. 15 
Conclusion ............................................................................................................................................. 17 
References .............................................................................................................................................. 17 
CHAPTER 2 - Cardiovascular risk profile: A clinic-based sample of youth living with HIV in the 
United States .............................................................................................................................................. 25 
Abstract .................................................................................................................................................. 25 
Introduction ........................................................................................................................................... 27 
Methods .................................................................................................................................................. 29 
Results .................................................................................................................................................... 34 
Discussion .............................................................................................................................................. 37 
References .............................................................................................................................................. 41 
CHAPTER 3 - Cigarette smoking and metabolic syndrome in youth living with HIV: Findings from 
electronic health records in the United States ........................................................................................ 52 
Abstract .................................................................................................................................................. 52 
Introduction ........................................................................................................................................... 54 
Methods .................................................................................................................................................. 56 
Results .................................................................................................................................................... 60 
References .............................................................................................................................................. 68 
CHAPTER 4 - Focus on single tablet regimen and lipid profile among youth living with HIV in 
multidisciplinary adolescent HIV care settings ...................................................................................... 78 
Abstract .................................................................................................................................................. 78 
Introduction ........................................................................................................................................... 80 
Methods .................................................................................................................................................. 82 
Results .................................................................................................................................................... 86 
Discussion .............................................................................................................................................. 90 
References .............................................................................................................................................. 94 
CHAPTER 5 – CONCLUSION ............................................................................................................. 102 
2 
 
Key Findings and Implications .......................................................................................................... 103 
Key Strengths ...................................................................................................................................... 109 
Limitations ........................................................................................................................................... 110 
Overall Conclusion and Future Directions ....................................................................................... 112 
References ............................................................................................................................................ 115 













Cardiac Risk Score1 Syntax…………………………………………………………………….…....…45 
Cardiac Risk Score2 Syntax………………………………………………………………….….……...45 
Table 1 Clinic Sites…………………………………………………………………………..…………46 
Figure 1. CONSORT-style diagram illustrating a comprehensive assessment of all missingness in the 
construction of Cardiac Risk Score1 and Cardiac Risk Score2………………………………………...47 
Table 2 Demographic and Clinical Characteristics of the Sample …………………….………………48 
Table 3 Bivariate Analysis by Detectable VL………………………………………….………………49 
Table 4 Bivariate Analysis by Low CD4 Cell Count………………………………………..…………50 




Table 1. Data Sources ……………………………………………...…………………………………..72 
Table 2. Demographic and Clinical Characteristics of the Sample …………..……………..………....73 
Figure 1. Metabolic syndrome among a clinic-based sample of YLH ……………….………………..74 
Table 3. Bivariate Association with Cigarette Smoking Status and VL …………….…………………75 
Table 4. Bivariate Association with Metabolic Syndrome and VL ……………………………………76 




Table 1. Data Sources ………………………………………………………………………………… 96 
Table 2. Components of Single Tablet Regimen ………………………………………………………97 
Table 3. Demographic and Clinical Characteristics of the Sample ………… ……………………...…98 
Table 4. Bivariate Analysis by Lipid Profile …………………………………………………………..99 
Table 5. Multivariable Logistic Regression by High Total Cholesterol†  …………………………….100 










CHAPTER 1 – INTRODUCTION 
Overview  
HIV infection has shown to be associated with increased risk for, and earlier occurrence 
of cardiovascular disease (CVD).1-3 Moreover, analysis of CVD in HIV-positive individuals 
indicates a two-fold risk for CVD events when compared to the general population.3-5 Emerging 
evidence suggests that HIV-related factors such as detectable viral load (VL) and immune 
dysfunction defined as CD4 cell count of less than 200,6 contribute substantially to increased risk 
of CVD for those with HIV resulting in premature atherosclerosis and accelerated aging.7-9 
Cigarette smoking is prevalent in at least 40% of people with HIV10-13 and significantly more 
common compared to the general population.14-16 The use of alcohol and drugs such as cocaine 
and other illicit drugs may further augment this association between HIV-related factors and 
premature development of CVD.17-20 The 2017 national Youth Risk Behavior Surveillance data 
showed that the prevalence of health risk behaviors associated with CVD is significantly higher 
among sexual minority students aged 10 to 24 years in the United States (U.S.).21 Nationwide, 
29.8% of students reported current alcohol use, 19.8% reported current marijuana use, and 14% 
had prescription drug misuse.21 In addition, 39.5% of students were sexually active and 9.7% of 
them had four or more sexual partners, 14.8% had obesity and 15.6% were overweight.21 Given 
the current guidelines of initiating antiretroviral therapy (ART) immediately after diagnosis in 
adolescents and young adults and that with each year an individual on ART ages, their risk for 
CVD increases because of ART’s effect on blood cholesterol and triglycerides,22-29 CVD 
prevention is critical in this population. However, the focus on CVD prevention and treatment in 
the context of HIV has exclusively targeted older adults who have experienced cardiovascular 
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events,4,30-34 while research on CVD prevention strategies for adolescents and young adults with 
HIV continues to be limited.  
Research Theme and Conceptual Basis 
With the growing burden of HIV-related CVD and 21% of all new HIV diagnoses in the 
U.S. were among youth in 2016,35 the cardiovascular risk profile for youth living with HIV 
(YLH) has yet to be developed. There is clearly a need for accurate risk stratification and 
aggressive primary and secondary prevention strategies in this important population.36 The 
conceptual framework for this study is informed by the Framingham multivariable risk 
algorithm37-40 and the increasing evidence that chronic immune activation and inflammation play 
a role in the pathogenesis of CVD in the context of HIV infection.41 Acute HIV infection results 
in low CD4+ cells throughout the gastrointestinal tract, which allows microbial translocation 
through the gut into the circulation, and this translocation may drive immune activation and 
inflammation – also known as leaky gut syndrome.41 Although metabolic changes leading to the 
development of atherosclerosis can start early in life, and are frequently undiagnosed in their 
early stages, the Framingham risk score and similar cardiac risk estimating equations are poorly 
validated in younger people due to their low absolute risk, age being the primary factor of the 
equation, and the frequent lack of traditional CVD risk factors.42,43  
The age alone is a non-modifiable risk factor contributing to the development of CVD in 
general population.44 Using the Cox proportional hazards regression model,45,46 the Framingham 
Heart Study constructed a gender-specific risk algorithm driven by age to estimate the 10-year 
risk of developing CVD. However, for HIV-positive populations, screening all patients 
regardless of age would allow health care providers to assess cardiovascular risk among YLH. 
With the development of Cardiac Risk Scores by removing age as a limiting factor in risk 
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calculations but keeping other factors (systolic blood pressure, total cholesterol, high-density 
lipoprotein (HDL) cholesterol, hypertension medication, cigarette smoking, and diabetes) from 
the Framingham risk score, primary care physicians can assess early risk for CVD among YLH. 
Given that obesity in childhood and young adulthood has repeatedly been shown to increase the 
risk of CVD later in life,42,43 it is valuable to assess routinely measured traits of metabolic 
syndrome using body mass index (BMI), blood glucose, systolic blood pressure, hypertension 
medications, HDL cholesterol, and triglycerides. These findings support a cardiovascular risk 
framework incorporating biomarkers, behavioral measures, and ART medications as predictors 
of a single multivariable CVD risk function in a U.S. based population of YLH (Figure 1).   
Public Health Significance 
CVD is the leading cause of death for both men and women in the United States47-49 with 
one out of every four deaths from a CVD event.48 CVD is a group of disorders that affects the 
heart or blood vessels.17 As a diagnostic category, CVD includes four major areas – coronary 
heart disease (CHD), cerebrovascular disease, peripheral artery disease (PAD), and aortic 
disease.50 CHD affects the blood vessels supplying heart muscle, and it is manifested by fatal or 
nonfatal myocardial infarction (heart attack), angina pectoris, and/or heart failure.17,50 It is the 
most common type of cardiovascular disease,17 killing more than 370,000 people annually.48 It is 
the cause of more than two-thirds of all heart disease-related deaths.51,52 Of the estimated 
735,000 annual incidence of myocardial infarction, 525,000 are new attacks and 210,000 are 
recurrent attacks.53 CHD alone in the United States accounts for $108.9 billion in expenses each 
year.54 
Cerebrovascular disease disrupts the blood vessels supplying the brain, and it is 
manifested by fatal or nonfatal stroke and transient ischemic attack.17,50 Stroke is the fifth leading 
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cause of death in the United States and is a major cause of adult disability.49,53 Of the 800,000 
CVD deaths each year, almost 130,000 Americans die from stroke – 1 in every 19 deaths from 
all causes.48 Of the estimated 795,000 annual incidence of stroke, about 610,000 are first events 
and 185,000 are recurrent stroke events.53 Stroke costs the United States an estimated $34 billion 
each year.53  
With ART being easily accessible and effective in many clinical settings,55,56 HIV-
positive individuals have longer life expectancy and are more likely to develop other chronic 
conditions, including CVD.8,17,57 Advances in treatment and prevention have led to a dramatic 
reduction in acquired immunodeficiency syndrome (AIDS)-related morbidity and mortality, and 
HIV has become a chronic condition.7,9,57 CHD outcomes and hospitalization rates have 
consistently been shown to be significantly higher among HIV-positive individuals in 
comparison to HIV-negative people.57,58 Researchers working on the Veterans Aging Cohort 
Study (VACS)  investigated whether HIV is associated with an increased risk of acute 
myocardial infarction after adjusting for all standard Framingham risk factors among a large 
cohort of HIV-positive and demographically and behaviorally similar uninfected veterans in 
care.1,34 The study found that through a median follow-up of 5.9 years, 82,459 veterans had 871 
acute myocardial infarctions and myocardial infarction incidence was consistently higher in 
veterans with HIV in three age brackets.1 The World Health Organization projected HIV/AIDS 
and CHD as 2 of the top 3 leading causes of both mortality and disability-adjusted life-years 
globally in the year 2030, which will pose a major challenge to public health and in the real 
world of practice.59 
 Among the many comorbidity conditions, CVDs have become of particular concern in 
the HIV-positive population. Why does HIV increase cardiovascular risks? HIV places a patient 
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at a higher risk for cardiovascular disease. This could be because of chronic inflammation of 
blood vessels that often accompanies HIV, long-term exposure to antiretroviral agents or a 
combination of both. In addition to environmental and genetic predisposition, HIV-positive 
patients present other factors that influence cardiovascular disease.7,9 HIV itself influences a state 
of persistent inflammation and immune activation, endothelial damage, increased thrombotic 
activity, higher oxidative stress, and metabolic abnormalities.7-9 There is growing evidence 
indicating HIV-accelerated inflammatory and immunologic processes (known to promote 
atherosclerosis) contributing to additional risk for CVD events in HIV-positive patients.7-9 Such 
a mechanism was demonstrated in the Strategies for Management of Antiretroviral Therapy 
(SMART) trial.60  
In SMART, HIV-positive patients were assigned to one of the two arms – continuous use 
of ART (viral suppression group), and treatment interruption (drug conservation group) with 
deferral of therapy until a CD4 count reduced to less than 250 cells per microliter.7-9 Patients in 
the drug conservation group compared with the viral suppression group experienced a higher 
hazard for AIDS or death, and more CVD events.7-9 Outcomes of subsequent studies from 
SMART showed that ART interruption was associated with significant increase in blood levels 
of interleukin-6 (a non-specific inflammatory biomarker) and D-dimer (a fibrin degradation 
product reflecting increased thrombotic activity that may be elevated in response to 
inflammatory stimuli and bacterial translocation.7-9 There is further evidence that HIV-positive 
patients with advanced immunosuppression (CD4 <200) and not fully virally suppressed (viral 
load >500) have a higher prevalence of elevated interleukin-6 and D-dimer.61  
On the other hand, the long-term exposure to antiretroviral agents (such as abacavir or 
protease inhibitors) still raises concerns for its potential deleterious metabolic and proatherogenic 
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effects.7-9 However, although some ARTs may be associated with antiviral-drug-induced 
metabolic changes, ART is a key factor in preventing CVD in people living with HIV and 
therefore has a positive net impact on inflammation, immune activation, and endothelial 
dysfunction.7-9 HIV itself may also be associated with other indicators of an increased risk of 
CHD, including higher calcium levels in the coronary arteries and may contribute to dysfunction 
of the heart muscle (myocardium).17 Finally, HIV-positive patients are frequently co-infected 
with hepatitis C virus (HCV), cytomegalovirus (CMV), or herpes viruses that may contribute to 
CVD by active inflammatory and immunological mechanisms, although HIV viral replication is 
suppressed.7-9 
HIV-positive patients share the same predisposing factor for the development of 
dyslipidemia, diabetes, or metabolic syndrome as the general population62 but there are many 
behavioral factors that a person can change. An extensive body of literature has established a 
high prevalence of traditional cardiovascular risk factors in people living with HIV compared to 
the general population.26,34,57,62,63 As explained above, other factors coexist such as the virus 
itself, ART, and/or HCV coinfection in HIV-positive patients, which could explain the higher 
prevalence of abnormal carbohydrate and lipid metabolism observed in HIV population.7 HIV-
positive patients are more likely to have an increase in lipids that can collect in their artery walls 
throughout their cardiovascular system. Lipid profiles are usually characterized by 
hypertriglyceridemia and low HDL.64 High triglycerides as well as high LDL (bad) cholesterol 
can increase a person’s likelihood for artery problems, and many PLWH have lower levels of 
HDL (good) cholesterol. There is a growing evidence demonstrating the importance of the 
cardiovascular risk factors, highlighting a strong association between HIV and CVD, one that is 
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even stronger than the link between ART and CVD.7 However, it is important to note that both 
ART and HIV infection may also induce dyslipidemia and diabetes.7  
Chronic inflammation may cause plaque, perhaps from ART or as a result of long-term 
exposure to the virus. Inflamed arteries are more likely to signal the body to send in additional 
infection-fighting white blood cells or t-cells, which may be in short supply due to the HIV. As a 
result, inflamed arteries trap more plaque leading to rupture and blood clot. Dietary habits appear 
to be worse in HIV-positive patients with many patients having a greater caloric intake.7 A case-
control study noted a significantly higher trans-, saturated-, and total fat and cholesterol 
consumption in HIV-positive patients compared to the healthy volunteers.7 Smoking in particular 
presents a greater risk of harm for HIV-positive patients both from the cardiovascular standpoint 
and increased risk of various cancers and emphysema. It is very common in HIV-positive 
patients7 and poses a significant challenge to HIV-positive patients and their providers.65 
According to a nationally representative cross-sectional study, adults with HIV were nearly twice 
as likely to smoke, compared to roughly 20% of the U.S. adult population, and that people living 
with HIV were less likely to quit smoking than the general population.66 
High blood pressure presents a potentially greater risk of HIV-positive patients than for 
someone who is HIV-negative. Interestingly, a recent meta-analysis showed lower prevalence of 
hypertension in HIV-positive patients compared to HIV-negative individuals.67 Several factors 
that are beyond one’s control can increase risk for heart attack and stroke. These include age, 
sex, and ethnicity. Tobacco screening and cessation strategies are important considerations as 
part of routine HIV care.66 Because the prevalence of smoking in HIV-positive patients is 
extremely high, the reduction of smoking would lead to the highest absolute reduction in CVD.9 
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However, this goal is not easily attainable without mutual respect in patient-provider 
relationships.   
The pathophysiology of accelerated CVD in young people with HIV is complex and 
multifactorial.68 CVD risk is increased in HIV-positive individuals.69-71 The underlying cause 
that drives the excess risk of CVD in the HIV-positive population is currently unclear, but likely 
involves a combination of factors. Some of the factors associated are predicted to be intrinsic to 
the individual and contribution of HIV itself and ART.71 Intrinsic factors include both non-
modifiable factors such as age, sex (males have increased risk of CVD), and modifiable factors 
(e.g., cigarette smoking, drug use, poor diet, and obesity).71 Traditional CVD risk factors tend to 
be more prevalent amongst HIV-positive individuals.34 Extensive research over the past decade 
has been conducted on modifiable factors such as high levels of cholesterol in the blood, high 
blood pressure, insulin resistance and high blood sugar, and abnormal accumulation of body fat 
in HIV-positive individuals.71 HIV infection alone, despite traditional risk factors, contributes to 
CVD risk.71 This risk increases as CD4 cells decrease,71 highlighting the importance of 
monitoring CD4 cell count and routinely collecting these data in the electronic health records 
(EHR) system in the U.S.   
HIV-positive individuals also suffer from immunologic changes from ART 
medications.71 ART is associated with increased CVD risk, although each drug differs in its 
contribution with lipid profile alterations, insulin resistance, and body fat.71 The degrees to which 
ART contribute to the increased risk of CVD in the HIV-positive population are unknown. Some 
data suggest an increased risk of CVD events with the use of protease inhibitors.44 Other classes 
of HIV medications such as first-line nucleoside reverse transcriptase inhibitors and integrase 
inhibitors are, however, associated with a favorable lipid profile.44 For example, tenofovir and 
12 
 
emtricitabine, do not have an adverse effect on lipid profiles.44 With the newer formulation of 
ART agents included as a component of single tablet regimens (STR), it is important to examine 
their impact on lipid abnormalities in YLH. It is recommended that HIV-positive individuals 
with CVD risk over 20% should adjust their ART, adhere to CVD therapeutic objectives, and 
make appropriate lifestyle changes.23,72,73 However, it is important to note that drug interactions 
(ART and drugs associated with CVD risk reduction) may have a significant clinical impact.  
Atherosclerosis, the pathological process that involves inappropriate lipid metabolism 
and activation of the innate and adaptive immune systems in the arterial wall,70,74 accelerates 
during adolescence. CVD risk in youth aged 18 to 24 years is underestimated despite the high 
prevalence of CVD risk factors75-78 and early signs of atherosclerosis in this group.79,80 
Adolescence and young adulthood are critical developmental phases and can have a significant 
impact on cardiovascular health.81 Obesity has more than tripled in youth over the past 30 
years.82 CVD risk increases by 2-4% for each year a youth is obese.83 As many as 33% of 
adolescents are overweight,76 and this excess weight leads to dyslipidemia84 and increases in 
metabolic syndrome,85 diabetes,86 and CVD78 risk. CVD contributes to half of CVD deaths and is 
one of the leading causes of death in adolescents.87 More than half of youth have at least one 
CVD risk factor, and this directly affects cardiovascular health throughout the lifespan.88 
Adolescence is the key age because many CVD risk factors surface in adolescence87,89-91 and 
track forward to adulthood.92 The American Health Association’s 2020 Strategic Impact Goals 
along with the National Health, Lung, and Blood Institute’s 2012 Expert Panel on Integrated 
Guidelines for Cardiovascular Health and Risk Reduction in Adolescents93 emphasize early 





Although there have been studies establishing links between HIV and CVD events, they 
mostly focus on older populations. The research on CVD prevention strategies for younger adults 
living with HIV is currently limited. This is of great concern since youth and young adults living 
with HIV face many challenges related to health and overall wellness, and is critical to the 
overall understanding of the impact of HIV infection on lifestyle and the relationship between 
HIV infection and CVD.  Routine, systematic, and comprehensive cardiac evaluation, including 
a thorough history and directed laboratory assays, is essential for the care of HIV-positive 
adolescents and young adults as cardiovascular illness has become a part of care for older adults 
living with HIV.94 Recommendations for CVD prevention in the general population include 
lifestyle modification such as smoking cessation and increased physical activity and an emphasis 
on prevention in adolescents and early adulthood when physical activity declines, smoking 
initiation occurs, and smoking addiction is initiated.95,96 Given the current guidelines of initiating 
ART immediately after diagnosis in adolescents and young adults and the relationship between 
ART and increased CVD risk, CVD prevention is critical in this population. 
To address these salient gaps, this dissertation contains three specific aims:   
AIM 1: Examine the association of HIV biomarkers (VL and CD4 cell count) with 
cardiovascular risk among YLH aged 14-26.  
Hypothesis 1a: Test the hypothesis that detectable VL will be positively associated with 
increased risk of CVD as compared to those with undetectable VL.  
Hypothesis 2b: Test the hypothesis that low CD4 cell count ≤ 200 will be positively 
associated with increased risk of CVD as compared to those with CD4 cell count > 200.  
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To achieve this aim, regression was used to develop cardiovascular risk profile in a clinic sample 
of U.S. based YLH. Detectable VL and CD4 cell count ≤ 200 were categorized into dichotomous 
variables and used as independent variables. Gender, systolic blood pressure, cigarette smoking, 
diabetes, diabetes, anti-hypertensive medication use, total cholesterol, and HDL cholesterol were 
used to construct Cardiac Risk Scores, the outcome variables, to build a multivariable linear 
regression model.   
AIM 2: Examine the association of cigarette smoking and metabolic syndrome with VL among 
YLH aged 14-26.  
Hypothesis 2a: Test the hypothesis that smoking will be positively associated with 
increased odds of having detectable VL as compared to those who do not smoke 
cigarette.  
Hypothesis 2b: Test the hypothesis that presence of metabolic syndrome will be 
positively associated with increased odds of having detectable VL as compared to those 
who do not have metabolic syndrome.  
To achieve this aim, metabolic syndrome variable with three categories were constructed based 
on the National Health, Lung, and Blood Institute (NHLBI) definition. Smoking and metabolic 
syndrome were used as independent variables. A dichotomous variable of detectable VL was 
used as the outcome variable to build a multivariable logistic regression model.   
AIM 3: Examine the association of STR and detectable VL with lipid abnormalities among YLH 
aged 14-26.  
Hypothesis 3a: Test the hypothesis that detectable VL will be positively associated with 




Hypothesis 3b: Test the hypothesis that detectable VL will be positively associated with 
increased risk of having high total cholesterol as compared to those with undetectable 
VL. 
Hypothesis 3c: Test the hypothesis that treatment with STR will be positively associated 
with decreased risk of having low HDL cholesterol as compared to those not on STR.   
Hypothesis 3d: Test the hypothesis that treatment with STR will be positively associated 
with decreased risk of having high total cholesterol as compared to those not on STR.   
To achieve this aim, the HIV medication data were used to create a patient-level dataset. 
Combination of three or more HIV medicines from at least two different HIV drug classes were 
coded as single tablet regimen. Detectable VL and STR were used as independent exposure 
variables to build a multivariable logistic regression model. A dichotomous variable of total 
cholesterol and HDL cholesterol were used as the outcome variables.   
Methods 
Study Design and Population 
To address the aforementioned specific aims, this dissertation consists of a secondary 
data analysis of de-identified EHR data extraction of YLH aged 14-26 receiving HIV medical 
care at 10 clinics participating in a network trial, the Scale It Up research project,97 which is 
currently underway for a longitudinal study, the 154 ATN Cascade Monitoring.98 Specific 
variables of interest from the 2016 baseline data files received from 10 clinical sites for the 154 
ATN Cascade Monitoring study98 were merged into a single analytic dataset. The study 
population included YLH if the extracted data contained standard of care and treatment visits at 
one of the participating sites between January 1, 2016 and December 31, 2016. To be included in 
these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4 cell count, 
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VL, systolic blood pressure, blood pressure medications, cholesterol panel, ART medications, 
and the International Statistical Classification of Disease and Related Health Problems Tenth 
Revision (ICD-10) diagnosis codes for diabetes, cigarette smoking, alcohol and drugs were 
required. 
Data Analysis  
The baseline sample size was 1093. In order to address our aim 1, we used two analytic 
samples (n = 813 for Cardiac Risk Score 1 and n = 398 for Cardiac Risk Score 2). In order to 
address our Aim 2 and aim 3, we used a sub-sample of 398 YLH. All analyses were performed in 
IBM SPSS Statistics 25 and syntax files were developed to construct new variables and recode 
some variables based on the analytic design for each study. The Framingham 10-year risk of 
general cardiovascular disease (2008 paper) calculator99 was used to construct Cardiac Risk 
Scores to satisfy Aim 1. The National Center for Chronic Disease Prevention (CDC) percentile 
data files on growth charts100 were downloaded to calculate BMI by sex and age to satisfy our 
aims.  
 We first described the sample overall based on demographic and clinical characteristics 
for all 3 studies. For Aim 1, we stratified the sample by VL and CD4 Cell count data to examine 
bivariate associations with cardiovascular risk using chi-square, ANOVA, and independent t 
tests. Next, we ran a series of three multivariable linear regression models with Cardiac Risk 
Score1 as a continuous outcome variable. Subsequentley, a separate series of three multivariable 
linear regression models examined the associatieon of each independent variable by Cardiac 
Risk Score2 as a continuous outcome variable. For Aim 2, we stratified the sample by VL status 
to examine bivariate associations with smoking and metabolic syndrome using chi-square, 
ANOVA, and independent t tests. Next, we ran a series of three multivariable linear regression 
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models with VL as a continuous outcome variable. For Aim 3, we stratified the sample across 
cholesterol outcomes documented in the EHR system to examine bivariate associations with 
detectable VL and STR using chi-square, ANOVA, and independent t tests. Next, we ran a series 
of three multivariable logistic regression models with total choesterol as a dichotomus outcome 
variable. Subsequently, a separate series of three multivariable logistic regression models 
examined the associatieon of detectable VL and treatment with STR by low HDL choesterol as a 
dichotomus outcome variable. 
Conclusion  
Although randomized controlled trials are considered the gold standard of research 
design, technological advances have opened the possibility for new trial designs, including 
integrating data from EHRs. This dissertation is the first to use multivariable modeling to 
examine the independent contributions of biomarkers, behavioral measures and ART 
medications on CVD risk in a U.S. based population of adolescents and young adults with HIV 
treated in routine practice. The use of multivariable models based on routinely available EHR 
data integrated into a common data model is an innovative approach to improving our 
understanding of important population health risk factors that may be modifiable in routine 
practice. The information gained may also provide valuable insight on how to design future 
clinical trials. The findings of this dissertation will help tailor current practice guidelines for 
CVD prevention in adolescents and young adults living with HIV.  
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CHAPTER 2 - Cardiovascular risk profile: A clinic-based sample of 
youth living with HIV in the United States 
 
Abstract 
Background: Accelerated atherosclerosis has been found in young individuals diagnosed with 
HIV. Previous research indicates that lower CD4 and higher plasma viral load (VL) significantly 
increased the risk of cardiovascular disease (CVD); however, this link is largely under-
investigated among youth living with HIV (YLH). We examined whether detectable VL and low 
CD4 count have significant associations with increased CVD risk among YLH aged 14-26y.    
Methods: This study used electronic health records from the Adolescent Medicine Trials 
Network 154 Cascade Monitoring baseline data extracted from multidisciplinary adolescent HIV 
care settings across the United States. Multivariable linear regression was used to assess the 
association between detectable VL and CD4 of ≤ 200 with Cardiac Risk Score1 (for those who 
had data on systolic blood pressure, cigarette smoking, diabetes, and anti-hypertensive 
medication use, n =813) and Cardiac Risk Score2 (for those who had data on systolic blood 
pressure, cigarette smoking, diabetes, anti-hypertensive medications use, total cholesterol, and 
HDL cholesterol, n = 398) adapted from the Framingham gender-specific algorithm. 
Results: The sample was predominantly Black and male with mean age of 21y. Overall, 47.8% 
had a detectable VL and 8.6% had a baseline CD4 of ≤ 200 indicating immune dysfunction. In 
bivariate analyses, we found significant associations between VL and CVD risk as measured by 
both cardiac risk scores (Cardiac Risk Score1, p < 0.001; Cardiac Risk Score2, p < 0.01). 
Comparing patients who had CD4 ≤ 200 with those who had CD4 > 200, the risk of CVD was 
significantly increased in patients who had CD4 ≤ 200 compared with those who had CD4 > 200 
as measured by Cardiac Risk Score2 (p < 0.01) but not with Cardiac Risk Score1. In the 
multivariable linear regression models, after adjusting for demographic and clinical covariates, 
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we found that for a 1000-point increase in VL copies/mL, there is a 38% increase in the 
likelihood of having CVD risk (Cardiac Risk Score2, B = 0.038, 95% CI = 0.011, 0.066; p < 
0.01. A small effect was observed for VL on increased CVD risk when measuring the strength of 
this association (β = 0.134). We observed similar findings with Cardiac Risk Score1. CD4 of ≤ 
200 was not found to be significantly associated with CVD risk. 
Conclusions: Higher plasma viral loads were associated with a small but statistically significant 
increased risk of CVD, independent of exposure to ART and presence of demographic and 
clinical covariates. Our findings demonstrate the independent contribution of detectable VL on 
cardiovascular risk and highlight the importance of maintaining VL suppression, monitoring 
metabolic health, and promoting self-management in YLH. 
 

















Cardiovascular disease (CVD) among HIV-positive populations is an issue that needs 
attention in the United States (U.S.). Although HIV-associated morbidity and mortality have 
decreased considerably with the introduction and widespread use of effective antiretroviral 
therapy (ART), 1-4 mortality rates among those with HIV remain 3 to 15 times higher than that of 
the general population.5-7 More than 50% of these deaths are due to comorbid conditions that are 
associated with inflammation,8-11 with CVD being the most prominent amongst these 
comorbidities.12-14 CVD has emerged as an important cause of death among HIV-positive 
populations (6.5% of a sample of 1876 deaths).12 The World Health Organization projected HIV 
and CVD as two of the top three leading causes of both mortality and disability-adjusted life-
years globally by 2030, which will pose a major challenge to public health.15 One study using 
national mortality data in the U.S. found that the proportion of deaths related to CVD increased 
more than twofold in HIV-positive populations compared to the general populations between 
1999 and 2013.16 The evidence to date suggests that CVD has become an increasingly common 
cause of death in HIV-positive populations since 1999.16,17 Therefore, understanding evolving 
cardiovascular risks in the HIV-positive populations is essential to improve routine clinical care 
of HIV-positive individuals as well as CVD prevention and treatment.16,17 
Youth living with HIV (YLH) show early signs of CVD and are an important subset of 
the HIV-positive populations. The prevalence of undiagnosed HIV infection is significantly 
higher among individuals aged 13-24 years compared to the overall 20% undiagnosed HIV 
infection prevalence in the U.S.18,19 Despite the fact that dramatic decreases in HIV transmission 
are achievable with early initiation of ART,20-22 recent research shows significant gaps in the 
HIV treatment cascade in younger individuals compared to older HIV-positive populations.18,19,22 
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In fact, young individuals aged 18-24 compared to older individuals have a lower uptake of HIV 
testing, diagnosis and treatment initiation which continues to present a significant challenge to 
epidemic control.19,22 Only 40% of HIV-positive individuals aged 13 to 29 in the U.S. are aware 
of their diagnosis22 compared to 80% of the national estimate of those 13 years and older who 
are aware they are HIV-positive.22,23  
A large cohort study examined California state-sponsored health insurance claims data of 
28,513 HIV-positive and 3,054,696 HIV-negative patients.24 Although the incidence of CVD 
events such as myocardial infarction (MI) in patients aged 18-24 years was low overall, it was 
increased in those with HIV compared with those who were HIV-negative (relative risk, 6.76; 
95% confidence interval [CI], 3.36-13.58 for men and relative risk, 2.47; 95% CI, 1.23-4.95 for 
women).24 In addition, accelerated atherosclerosis has been found in young individuals 
diagnosed with HIV without traditional CVD risk factors.25 Therefore, it is important to monitor 
cardiac activity, HIV and immunologic biomarkers (i.e., CD4 cell count and viral load [VL]) of 
young individuals diagnosed with HIV and continue to collect data from this population.  
The pathophysiology of accelerated CVD in young individuals with HIV is currently 
unknown. However, there is a growing body of evidence to suggest increased CVD risk among 
those with lower CD4 cell counts and higher viral loads.13,26-29 In a nested case-control study of 
289 HIV-positive French patients with a prospectively recorded first-time MI matched with 884 
HIV-positive controls with no history of MI, lower nadir CD4 count and higher plasma VL were 
associated with a significant increase in MI after adjusting for ART and traditional risk factors.28 
Similarly, in a retrospective analysis of 3,068 HIV-positive patients in the Netherlands, those 
with immune dysfunction characterized by CD4 cell count of less than 200 cells/mm3 after two 
years of ART initiation had higher estimated five-year cardiovascular event rates (4.7%) than 
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those with improved CD4 cell count (2 to 2.6%).29 Furthermore, a large observational cohort 
study of 2,006 HIV-positive patients who received care at the Vanderbilt Comprehensive Care 
Clinic in Tennessee between 1998 and 2012 suggested an association between low CD4 to CD8 
ratio and cardiovascular risk, particularly among younger patients.30   
The evidence suggests that YLH may have higher cardiovascular risk, which is currently 
under-recognized and under-researched in the U.S. There are currently no published data 
regarding the classic cardiovascular risk factors of dyslipidemia, hypertension, diabetes, and 
smoking among YLH aged 14-26 years. Although metabolic changes leading to the development 
of atherosclerosis can start early in life, and are frequently undiagnosed in their early stages, the 
Framingham risk score and similar cardiac risk estimating equations are poorly validated in 
younger people due to their low absolute risk and the frequent lack of traditional CVD risk 
factors.31,32 The current study was undertaken to develop cardiovascular risk profiles in a sample 
of US-based YLH and to compare their cardiovascular risk profiles by VL And CD4 status. We 
hypothesized that detectable VL and CD4 count ≤ 200 would be associated with increased CVD 
risk. 
Methods 
Study Design and Population 
 The Adolescent Medicine Trials Network (ATN) Scale It Up research program consists of 
six study protocols as previously described33 and one of them is the ATN 154 Cascade 
Monitoring electronic health records (EHR) initiative.34 De-identified EHR data were requested 
from 10 participating sites for the baseline year 2016 (see Table 1). The 10 sites routinely 
provide the HIV care continuum (also known as the HIV treatment cascade) to YLH that begins 
with a diagnosis followed by linkage to an HIV healthcare provider who can engage youth in 
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regular HIV medical care, initiating ART, and achieving viral suppression. The Institutional 
Review Boards of both Florida State University and the City University of New York approved 
to conduct analyses of de-identified data.  
The study population included YLH if the extracted data contained standard of care and 
treatment visits at one of the participating sites between January 1, 2016 and December 31, 2016. 
Baseline data extraction cycle was launched in December 2017 and was completed in April 
2018. Once the extracted data files were received and verified for each site, data from 10 sites 
were cleaned and merged to produce a single analytic dataset of 1,093 YLH. To be included in 
these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4 cell count, 
VL, systolic blood pressure, blood pressure medications, cholesterol panel, ART medications, 
and the International Statistical Classification of Disease and Related Health Problems Tenth 
Revision (ICD-10) diagnosis codes for diabetes, cigarette smoking, alcohol and drugs were 
required. Because Brooklyn, Miami, and Philadelphia did not provide gender and systolic blood 
pressure data, these 3 sites were excluded from further analyses.  
Measures 
 Demographics. We defined age as a continuous variable in years as reported by site. 
Gender, race, and ethnicity definitions varied within a site’s data download. These demographic 
variables were constructed as reported by site. For gender we constructed a binary variable of 
male and female. Race/ethnicity variable was categorized into Black, Latino, White, Hispanic, 
and patients of any other race were reported as Other. Missing race for two patients were kept as 
missing data and removed from these analyses.  
 HIV and immunologic biomarkers. Earliest VL values in “copies/mL” by date were used 
from each site. VL was missing for 5.8% of the sample. Missing VL results for 47 patients were 
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not included in these analyses. VL was log-transformed for analysis as a continuous outcome. 
Detectable VL threshold as reported by site was coded as a dichotomous variable. Based on the 
guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we 
defined immunocompromised as CD4 T lymphocyte cell count of less than or equal to 200.35,36 
CD4 cell count, a measure of immune status was missing for 27% of the sample. Missing CD4 
results for 220 patients were not included in these analyses. CD4 cell count was divided by 100 
to enhance the interpretability of the coefficients to correspond to a 100-cell increase rather than 
a 1-cell increase.   
 ART medication. All prescribed HIV medications were coded into a dichotomous variable 
where 0 = no prescribed medication and 1 = at least one prescribed medication. Missing values 
for 92 patients were assumed to not have received prescriptions and was combined with the non-
ART category.    
 Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510, 
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drug 
dependence such as amphetamines, cannabis, cocaine, hallucinogens, and opioid. Substance 
abuse was treated as a dichotomous variable. Missing values (n=714 values) were assumed as 
non-substance-abuse because there are issues around documentation and disclosure of alcohol 
and drugs use in clinical settings. The use of diagnostic codes as a proxy for substance abuse 
diagnoses underestimates the prevalence of alcohol and drug use problems.36  
 Body mass index (BMI). BMI was calculated based on weight and height (kg/m2). If 
multiple values for a given patient were present in EHR, values from the earliest date were used. 
Seven patients with missing values were removed from further analyses.  
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 Cardiac risk scores. We adapted the gender-specific cardiovascular risk algorithm 
developed by the Framingham Heart Study,86,8 to construct a cardiovascular risk variable 
referred to as Cardiac Risk Score1 using clinic-based predictors that are routinely obtained in 
primary care and do not require laboratory testing. These variables included systolic blood 
pressure, anti-hypertensive medication use, current smoking, and diabetes status. Missing data 
were present for gender and systolic blood pressure. 
We also constructed a second cardiovascular risk variable referred to as Cardiac Risk 
Score2 that used routinely obtained clinic-based predictors incluidng laboratory testing. These 
variables included systolic blood pressure, anti-hypertensive medication use, current smoking, 
diabetes, total cholesterol, and HDL cholesterol. Missing data were present for gender, total 
cholesterol, HDL cholesterol, and systolic blood pressure (see Figure. 1, CONSORT-style 
diagram illustrating a comprehensive assessment of all missingness in the construction of 
Cardiac Risk Score1 and Cardiac Risk Score2). Because age is the strongest predictor of CVD 
risk and that almost all multivariable risk algorithms are used to assess risk of CVD events in 
older adults, it was removed from the equations. We set age = 21y. Following the convention of 
the existing CVD prediction algorithm developed based on data obtained from the Framingham 
Heart Study, we constructed a separate gender-specific multivariable risk funciton aglorithm for 
males vs. females.37 The syntax for both Cardiac Risk Score1 and Cardiac Risk Score2 can be 
found in the Appendix. 
Data Analysis 
 HIV-positive patients who had health records of systolic blood pressure, anti-
hypertensive medication use, current smoking, and diabetes status in 2016, were included in the 
first analytic sample for Cardiac Risk Score1 (n =813). We then constructed a second analytic 
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sample for Cardiac Risk Score2 (n = 398) in order to incorporate total cholesterol and HDL 
cholesterol with the above-mentioned routinely obtained clinic-based predictors.  
First, we performed a descriptive analysis of demographic and clinical characteristics of 
the sample. Second, we conducted bivariate analyses of the sample using chi-square and 
independent samples t-tests with detectable VL and low CD4 count as a nominal variable. 
Finally, we ran a series of three multivariable linear regression models with Cardiac Risk Score1 
as a continuous outcome variable. The first model was constructed to determine whether 
detectable VL was associated with cardiovascular risk. The second model was constructed to 
examine whether immune dysfunction characterized by CD4 cell count ≤ 200 was associated 
with cardiovascular risk. The third model examined the combined effect of detectable VL and 
low CD4 count with cardiovascular risk. The three regression models were repeated with 
Cardiac Risk Score2 as the outcome. Covariates included age, race/ethnicity, gender, being 
prescribed ART medication, substance dependence, and BMI.  
The linear regression coefficients were evaluated using unstandardized beta (B) as the 
point estimate and an interpretation of its meaning and/or magnitude; confidence interval (CI) for 
the variability around that point estimate so we know how precise it is; and p-value for statistical 
significance. Using Cohen’s criteria as described as small (.10), medium (.30), and large (.50), 
standardized beta (β) served as an effect size estimate of independent variables on the dependent 
variable. All analyses were performed in IBM SPSS Statistics 25 and syntax files were 
developed to construct new variables and recode some variables based on the analytic design. 




 Demographic and clinical characteristics of the analytic sample (n = 813) are displayed in 
Table 1. The mean age was 21 with a range of 14 to 26 years (SD = 2.6). The sample was 
predominantly of racial and ethnic minorities – 70.3% identified as Black, 10.9% identified as 
Latino, 10% identified as White, and 8.9% identified as any other race. More than two thirds 
(69.2%) of the sample were men and 30.8% were reported by site as women. Among those with 
VL data, nearly half (47.8%) had a detectable VL, while 52.2% had an undetectable VL. Among 
those with a detectable VL, 247 (30%) had > 1,000 copies/mL. Among those with a CD4 cell 
count value available, 91.4% had a baseline count of > 200, while 8.6% had a baseline count of ≤ 
200 indicating immunocompromised status. Of the 813 YLH, 88.6% were currently taking ART 
and 11.4% were not on ART medication. Among those sites with the required data for this study, 
Tampa (n = 219) and Memphis (n = 187) had the largest sample size (26.9% and 23%, 
respectively). The mean BMI was 25 kg/m2 (SD = 6.7). The mean Cardiac Risk Score1 based on 
systolic blood pressure, anti-hypertensive medication use, current smoking, and diabetes status 
was 0.062 (SD = 0.039). The mean Cardiac Risk Score2 based on systolic blood pressure, anti-
hypertensive medication use, current smoking, diabetes, total cholesterol, and HDL cholesterol 
was 0.672 (SD = 0.401).  
Bivariate correlates of HIV and immunologic biomarkers 
 Demographic and clinical correlates. Examining the demographic and clinical indicators 
by HIV biomarker, several general trends emerged as shown in Table 2. First, patients who had 
detectable VL, compared to those who had undetectable VL, were more likely to be Black 
(74.5% vs. 67.0%; χ² = 9.881; p < 0.05). Second, almost three-quarters of patients with 
detectable VL were men (72.7%) compared to 65.2% of patients without detectable VL (χ² = 
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4.912; p < 0.05). In addition, 87.7% of those with detectable VL were on ART medication 
compared to 92.5% of those with undetectable VL (χ² = 4.975; p < 0.05). Last but not least, 
15.8% of those with detectable VL had CD4 cell count ≤ 200 compared to only 2.5% among 
those with undetectable VL (χ²[1] = 32.326; p ≤ 0.001).  
The 10-year risk of developing CVD was estimated using two cardiovascular risk 
variables, Cardiac Risk Score1 (n = 813) and Cardiac Risk Score2 (n = 398). In bivariate 
analyses, we found significant associations between VL and CVD risk as measured by both 
cardiac risk scores (Cardiac Risk Score1, p < 0.001; Cardiac Risk Score2, p < 0.01). No 
significant differences (p > 0.05) were found between the demographic characteristics and the 
immunologic biomarker, CD4 cell count, as displayed in Table 3. Comparing patients who had 
CD4 cell count ≤ 200 with those who had CD4 cell count > 200, no significant difference was 
found in Cardiac Risk Score1. With Cardiac Risk Score2, the risk of CVD was significantly 
increased in patients who had CD4 cell count ≤ 200 compared with those who had CD4 cell 
count > 200 (p < 0.01).  
Multivariable analyses of cardiac risk scores 
Cardiac Risk Score1. Multivariable regression analysis of Cardiac Risk Score1 from 
demographic and clinical characteristics including HIV and immunologic biomarkers is shown in 
a series of model 1 in Table 4. Model 1A: Cardiac Risk Score1 with VL results plus demographic 
and clinical covariates. After adjusting for age, race/ethnicity, gender, ART medication, 
substance abuse diagnosis, and BMI, we found significant positive association between VL and 
CVD risk as measured by Cardiac Risk Score1 (p < 0.01). We found that for a 1-unit increase in 
VL, there is a 0.002 increase in log-likelihood of having CVD risk (B = 0.002; 95% CI = 0.000, 
0.003). On a scale that may be more meaningful for clinicians and patients themselves, this 
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indicates that a 1,000-point increase in VL (for example, from having a VL of 1,000 to having a 
VL of 2,000), there is a 2% increase in the likelihood of having CVD risk. While 0.002 is the 
best estimate of this association, we are 95% confident that the true beta falls between 0.000 and 
0.003. Because this 95% CI does not include 1, the association is statistically significant at the 
0.05 level. Therefore, the model is useful for predicting that there is association between VL and 
CVD risk. A small effect was observed for VL on increased CVD risk when measuring the 
strength of this association since the standardized beta value was closer to 0.1 (β = 0.067). Model 
1B: Cardiac Risk Score1 with CD4 results plus demographic and clinical covariates. After 
adjusting for age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, 
CD4 cell count was not significantly associated with CVD risk. Model 1C: Cardiac Risk Score1 
with VL and CD4 results together plus demographic and clinical covariates. After adjusting for 
age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, we found 
significant positive association between VL and CVD risk as measured by Cardiac Risk Score1 
(p < 0.01), while CD4 cell count was not (p = 0.653). We found that the findings of this model 
were similar to model 1A. Although a small effect was observed when measuring the strength of 
the association between VL and increased CVD risk, the effect size slightly increased with this 
model (β = 0.088).  
Cardiac Risk Score2. Multivariable regression analysis of Cardiac Risk Score2 from 
demographic and clinical characteristics including HIV and immunologic biomarkers is shown in 
a series of model 2 in Table 4. Model 2A: Cardiac Risk Score2 with VL results plus demographic 
and clinical covariates. After adjusting for age, race/ethnicity, gender, ART medication, 
substance abuse diagnosis, and BMI, we found significant positive association between VL and 
CVD risk as measured by Cardiac Risk Score2 (p < 0.01). We found that for a 1-unit increase in 
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VL, there is a 0.038 increase in log-likelihood of having CVD risk (B = 0.038; 95% CI = 0.011, 
0.066). On a scale that may be more meaningful for clinicians and patients themselves, this 
indicates that a 1,000-point increase in VL (for example, from having a VL of 1,000 to having a 
VL of 2,000), there is a 38% increase in the likelihood of having CVD risk. While 0.038 is the 
best estimate of this association, we are 95% confident that the true beta falls between 0.011 and 
0.066. Because this 95% CI does not include 1, the association is statistically significant at the 
0.05 level. Therefore, the model is useful for predicting that there is association between VL and 
CVD risk. A small effect was observed for VL on increased CVD risk when measuring the 
strength of this association since the standardized beta value was 0.1 (β = 0.134). Model 2B: 
Cardiac Risk Score2 with CD4 results plus demographic and clinical covariates. After adjusting 
for age, race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, CD4 cell 
count was not significantly associated with CVD risk. Model 2C: Cardiac Risk Score2 with VL 
and CD4 results together plus demographic and clinical covariates. After adjusting for age, 
race/ethnicity, gender, ART medication, substance abuse diagnosis, and BMI, we found 
significant positive association between VL and CVD risk as measured by Cardiac Risk Score2 
(p < 0.05), while CD4 cell count was not (p = 0.544). We found that the findings of this model 
were similar to model 2A. Although a small effect was observed when measuring the strength of 
the association between VL and increased CVD risk, the effect size slightly increased with this 
model (β = 0.146).  
Discussion 
This study focused on the development of CVD risk profiles and the associations of HIV 
and immunologic biomarkers with cardiac risk scores in YLH aged 14-26y. Both cardiac risk 
scores demonstrated similar findings upon examining the associations with HIV and 
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immunologic biomarkers. Notably, VL was found to be significantly related to CVD risk after 
adjusting for demographic and clinical covariates, highlighting the importance of linking 
metabolic and HIV care in routine clinical practice.  
The American Heart Association (AHA) developed a Health Campaign for Life’s Simple 
7, which emphasizes early prevention in adolescence38-40 to prevent the development of CVD 
later in life and help curtail the high costs associated with CVD. The AHA’s Life’s Simple 7 
metrics include core health behaviors (smoking, physical activity, diet, and weight) and clinical 
risk factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular 
health.38 With the growing burden of HIV-related CVD and 21% of all new HIV infection being 
diagnosed among youth in the U.S.,41 it is important to examine the overall cardiovascular risk 
profile of YLH as opposed to focusing on any one single risk factor. The two US-based cohorts 
of HIV-positive patients – the Women’s Interagency HIV Study (WIHS) and the Multicenter 
AIDS Cohort Study (MACS) used the Framingham Risk Score equations to estimate the 10-year 
risk of developing CVD among 1455 women and 931 men.42 The findings from these two 
cohorts demonstrated that among HIV-positive men, 17% had high predicted CVD risk in 
contrast with HIV-negative men (11%) whereas among HIV-positive women, 12% had high 
predicted CVD risk which was similar to HIV-negative women.42 However, while the 
Framingham Risk Score developed for use in the general population appears to be well-
calibrated in some populations, it overestimates or underestimates 10-year cardiovascular risk in 
those with HIV, depending on individual risk factors with chronic immune activation and 
inflammation.43,44 
 Our findings showed that detectable VL was associated with significantly increased risk 
of CVD, both at the bivariate level and in multivariable linear regression models. Higher plasma 
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VLs were associated with a small but statistically significant increased risk of CVD, independent 
of exposure to ART and presence of demographic and clinical covariates. These findings 
contribute to our understanding of the broad spectrum of the VL-CVD risk relationship. VL can 
fluctuate over time depending on patients’ access to treatment, retention in care, response to HIV 
treatment, and medication adherence. Prior research has shown that the Framingham Risk Score 
is poor at stratifying lifetime risk in younger individuals and has been unable to estimate CVD 
risk in populations below age 30.45 Immunologic biomarker, CD4 cell count, was only associated 
with Cardiac Risk Score2 at the bivariate level. Upon combining routinely obtained clinic-based 
predictors with laboratory testing, lower CD4 cell count was associated with a statistically 
significant increased risk of CVD in patients who had a baseline count data.  
The utility of our risk scores without age adds new knowledge in the assessment of CVD 
risk prediction in young HIV-positive populations. Removing age from the risk equations as a 
significant factor may have important implications for clinical decision-making regarding 
treatment thresholds in YLH. Since the Framingham Risk Score and similar cardiac risk 
estimating equations place significant weight on age in predicting absolute risk, the use of our 
risk scores provide important insights to classify YLH at high risk for CVD. The current study 
sets the stage for future research that could further test this approach and can be extended to non-
HIV youth populations. Since we found similar results between the two risk scores the simpler 
version can be utilized as a cost-effectiveness method for HIV-positive youth at high risk for 
CVD by utilizing routinely obtained clinic-based predictors as laboratory testing is not required. 
Nevertheless, researchers need to evaluate periodically for potential biases that were not apparent 
in this study. In addition, the use of continuous risk scores may prevent from creating an 
arbitrary classification of high CVD risk as predicted by the Framingham Risk Score. 
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Although the current findings are based on a multi-clinic sample, there are potential 
limitations. First, the study design was cross-sectional and thus no causal inference may be 
drawn. Our findings may also not be generalizable to the entire YLH population in the U.S. or 
elsewhere. Future research should attempt to test these associations in longitudinal data to 
observe changes over time. Second, we were unable to define undetectable VL as a VL test result 
of < 200 copies/mL due to incomplete medical records extracted from multiple sites with some 
sites reporting in text (detectable/undetectable) as opposed to providing the actual VL values. 
Some misclassification may have occurred. Third, we were unable to provide the lower limit 
detection threshold because sites utilized various laboratories and assays with varying detection 
limits to perform VL testing. Another limitation in the current data was the number of missing 
data, particularly relating to cholesterol. We had to drop youth from three of the highest 
prevalence areas in the U.S. EMRs with more complete data should be prioritized. 
Finally, this analysis was also limited by the fact that we used unvalidated cardiac risk 
scores and the data we had were not sufficient to conduct any validation of the score. Our 
Cardiac Risk Score1 was developed based on routinely available clinical data. Our Cardiac Risk 
Score2 included both routinely available and laboratory data. Age wasn’t a limiting factor in 
calculating both of these risk scores. The calculations were not based on the age value – all 
participants with enough data to calculate risk were assumed to be 21. Since no study has 
validated the risk scores we used, there is a need for validation study to ensure these scores are 
valid and clinically meaningful. By using a population-wide longitudinal dataset, future step 
should include conducting external validation of our modified risk scores for both adolescent and 
adult with no CVD events to determine model applicability at a different time. As described in 
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prior studies, we can assess the overall ability of our cardiac risk prediction scores using Harrel’s 
C-statistics.46-48     
Despite these limitations, the current study is innovative in that it utilized the EHRs of 
813 YLH from 7 ATN clinics to examine the independent contributions of HIV and immunologic 
biomarkers on CVD risk in a U.S.-based cohort of YLH treated in routine practice. EHRs 
provided us with the opportunity to include two innovative design features in this study: (a) the 
inclusion of HIV outcomes data from clinic-based patients lowered the costs of conducting the 
study; and (b) the ability to include ICD-10 codes to identify clinical covariates used in the 
analyses. These findings have implications for the development of a single multivariable risk 
prediction tailored to YLH. Future research is warranted to test a risk equation including VL in 
relation to CVD outcomes. This study highlights the need for further research evaluating the 
inclusion of HIV-specific variables, including HIV medications (e.g., number of years taking 
ART) into tailored risk prediction algorithms. It has the potential for becoming an essential tool 
which can be made available online such as through UpToDate, a software system used as a 
point-of care medical resource. As the presence of a detectable VL was found to be significantly 
associated with CVD risk, the findings of our study highlight the relevance of considering HIV 
infection as an additional CVD risk factor and providing CVD prevention in YLH in routine 
practice.  
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Cardiac Risk Score1 Syntax 
 
DO IF Male = 1 AND BP_Meds = 0. 




DO IF Male = 0 AND BP_Meds = 0. 





DO IF Male = 1 AND BP_Meds = 1. 




DO IF Male = 0 AND BP_Meds = 1. 





DO IF Male = 1. 
COMPUTE Risk1 = 100*(1 - RiskPeriodFactorM**EXP(RiskFactors_R1)). 
END IF. 
DO IF Male = 0. 




Cardiac Risk Score2 Syntax 
 
DO IF Male = 1 AND BP_Meds = 0. 





DO IF Male = 0 AND BP_Meds = 0. 
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorW)+(TotalCholFactorW*(LN(TotalChol)) 






DO IF Male = 1 AND BP_Meds = 1. 
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorM)+ (TotalCholFactorM*(LN(TotalChol))) 




DO IF Male = 0 AND BP_Meds = 1. 
COMPUTE RiskFactors_R2 = ((LN(21))*AgeFactorW)+(TotalCholFactorW*(LN(TotalChol))) 




DO IF Male = 1. 
COMPUTE Risk2 = 100*(1 - RiskPeriodFactorM**EXP(RiskFactors_R2)). 
END IF. 
DO IF Male = 0. 




Table 1. Clinic Sites 
City Organization 
Baltimore Johns Hopkins University, Maryland 
Birmingham University of Alabama at Birmingham, Alabama 
Brooklyn SUNY Downstate Medical Center, New York 
Los Angeles Children’s Hospital Los Angeles, California 
Memphis St. Jude Children’s Research Hospital, Tennessee 
Miami University of Miami, Florida 
Philadelphia Children’s Hospital of Philadelphia, Pennsylvania 
San Diego University of California San Diego, California 
Tampa University of South Florida, Florida 
Washington DC 










Figure 1. CONSORT-style diagram illustrating a comprehensive assessment of all 














Table 2. Demographic and Clinical Characteristics of the Sample (N = 813) 
  n % 
Race/Ethnicity (n = 811)   
Black 570 70.3 
Latino 88 10.9 
White 81 10.0 
Other 72 8.9 
Gender    
Male 563 69.2 
Female 250 30.8 
ART Medication    
Currently on ART medication  720 88.6 
Not reportedly on ART medication 93 11.4 
Viral Load (n = 766)   
Detectable VL 366 47.8 
Undetectable VL 400 52.2 
CD4 Cell Count (n = 593)   
Baseline count ≤ 200 51 8.6 
Baseline count > 200 542 91.4 
Substance Abuse Diagnosis   
Diagnosed with substance abuse 99 12.2 
Not diagnosed with substance abuse 714 87.8 
ATN Clinical Site   
Baltimore 90 11.1 
Birmingham 61 7.5 
Los Angeles 84 10.3 
Memphis 187 23.0 
San Diego 101 12.4 
Tampa 219 26.9 
Washington DC 71 8.7 
   
 M SD 
Age (Range: 14 - 26; Mdn. = 21) 21 2.6 
BMI (Range: 4.8 - 69.5; Mdn. = 23.3; n = 806) 25 6.7 
Cardiac Risk Score1* (Range: 0.01 - 0.26; Mdn. = 0.061)  0.062 0.040 
Cardiac Risk Score2** (Range: 0.17 - 4.05; Mdn. = 0.569; n = 398)  0.672 0.401 
*Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, 
smoking, diabetes, and anti-hypertensive medication use.  
**Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, 




Table 3. Bivariate Analysis by Detectable VL  
  Total Sample   Detectable VL   Undetectable VL       
 N = 766  n = 366  n = 400  Test Statistics 
  n %  n %  n %  df χ² 
Race/Ethnicity (n = 764)            
Black 539 70.5  271 74.5  268 67.0  3 9.881* 
Latino 85 11.1  43 11.8  42 10.5    
White 73 9.6  27 7.4  46 11.5    
Other 67 8.8  23 6.3  44 11.0    
Gender             
Male 527 68.8  266 72.7  261 65.2  1 4.912* 
Female 239 31.2  100 27.3  139 34.8    
ART Medication             
Currently on ART medication  691 90.2  321 87.7  370 92.5  1 4.975* 
Not reportedly on ART medication 75 9.8  45 12.3  30 7.5    
CD4 Cell Count (n = 593)            
Baseline count ≤ 200 50 8.6  42 15.8  8 2.5  1 32.326*** 
Baseline count > 200 532 91.4  224 84.2  308 97.5    
Substance Abuse Diagnosis            
Diagnosed with substance abuse 97 12.7  49 13.4  48 12.0  1 0.333 
Not diagnosed with substance abuse 669 87.3  317 86.6  352 88.0    
            
 M SD  M SD  M SD  df F 
Age  21 2.6  21 2.5  21 2.7  764 2.990 
BMI (n = 762) 25 6.8  25 6.6  26 6.9  760 3.626 
Cardiac Risk Score1  0.062 0.040  0.067 0.042  0.058 0.037  764 2.049*** 
Cardiac Risk Score2 (n = 394) 0.672 0.672   0.735 0.452   0.626 0.348   392 4.577** 
Note: *p <0.05. ** p <0.01. ***p <0.001.            
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.  




Table 4. Bivariate Analysis by Low CD4 Cell Count 
  Total Sample   CD4 Cell Count ≤ 200   CD4 Cell Count > 200       
 N = 593  n = 51  n = 542  Test Statistics 
  n %  n %  n %  df χ² 
Race/Ethnicity (n = 591)            
Black 431 72.9  44 88.0  387 71.5  3 6.548 
Latino 63 10.7  3 6.0  60 11.1    
White 48 8.1  1 2.0  47 8.7    
Other 49 8.3  2 4.0  47 8.7    
Gender             
Male 420 70.8  36 70.6  384 70.8  1 0.002 
Female 173 29.2  15 29.4  158 29.2    
ART Medication             
Currently on ART medication  529 89.2  48 94.1  481 88.7  1 1.397 
Not reportedly on ART medication 64 10.8  3 5.9  61 11.3    
Viral Load (n = 582)            
Detectable VL 266 45.7  42 84.0  224 42.1  1 32.326*** 
Undetectable VL 316 54.3  224 42.1  308 57.9    
Substance Abuse Diagnosis             
Diagnosed with substance abuse 86 14.5  9 17.6  77 14.2  1 0.445 
Not diagnosed with substance abuse 507 85.5  42 82.4  465 85.8    
            
 M SD  M SD  M SD  df F 
Age  21 2.6  21 2.5  21 2.5  591 0.042 
BMI (n = 591) 25 6.8  24 5.8  25 7.0  589 3.357 
Cardiac Risk Score1 0.062 0.039  0.066 0.046  0.060 0.037  591 1.223 
Cardiac Risk Score2 (n = 343) 0.672 0.401   0.864 0.741   0.621 0.338   341 8.712** 
Note: *p <0.05. ** p <0.01. ***p <0.001.            
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.  
Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-hypertensive medication use, total 







Table 5. Multivariable Linear Regression Models by Cardiac Risk Scores  
 Model 1 with Cardiac Risk Score1 
  Model 1A with VL Results   Model 1B with CD4 Results   Model 1C with VL and CD4 Results 
 Unstandardized  Standardized  Unstandardized  Standardized  Unstandardized  Standardized 
  B SE 95% CI   β   B SE 95% CI   β   B SE 95% CI   β 
Age 0.001 0.000 (0.000, 0.002)  0.072**  0.002 0.000 (0.001, 0.003)  0.123***  0.002 0.000 (0.001, 0.003)  0.135*** 
Race/Ethnicity  0.002 0.001 (0.000, 0.004)  0.056*  0.002 0.001 (0.000, 0.004)  0.043  0.001 0.001 (-0.001, 0.004)  0.036 
Gender  0.061 0.002 (0.057, 0.065)  0.710***  0.058 0.002 (0.053, 0.063)  0.691***  0.059 0.003 (0.054, 0.064)  0.696*** 
ART Medication  0.001 0.003 (-0.005, 0.008)  0.010  
-
0.001 0.003 (-0.008, 0.006)  -0.007  0.001 0.004 (-0.006, 0.008)  0.006 
Substance Abuse Diagnosis  0.015 0.003 (0.009, 0.020)  0.124***  0.017 0.003 (0.011, 0.023)  0.159***  0.015 0.003 (0.008, 0.021)  0.136*** 
BMI  0.000 0.000 (0.000, 0.001)  0.057*  0.000 0.000 (0.000, 0.001)  0.055  0.000 0.000 (0.000, 0.001)  0.053 
Viral Load 0.002 0.001 (0.000, 0.003)  0.067**  --- --- ---  ---  0.002 0.001 (0.001, 0.004)  0.088** 
CD4 Cell Count --- --- ---   ---   0.000 0.000 (-0.001, 0.000)   -0.028   0.000 0.000 (-0.001, 0.001)   0.015 
Note: *p <0.05. ** p <0.01. ***p <0.001.               
                  
 Model 2 with Cardiac Risk Score2 
  Model 2A with VL Results   Model 2B with CD4 Results   Model 2C with VL and CD4 Results 
 Unstandardized  Standardized  Unstandardized  Standardized  Unstandardized  Standardized 
  B SE 95% CI   β   B SE 95% CI   β   B SE 95% CI   β 
Age 0.012 0.008 (-0.003, 0.027)  0.081  0.023 0.008 (0.007, 0.039)  0.152**  0.024 0.008 (0.008, 0.040)  0.158** 
Race/Ethnicity  0.039 0.021 (-0.002, 0.081)  0.091  0.040 0.022 (-0.002, 0.082)  0.096  0.045 0.022 (0.002, 0.088)  0.105* 
Gender  0.164 0.044 (0.077, 0.251)  0.188***  0.163 0.045 (0.074, 0.252)  0.194***  0.170 0.046 (0.080, 0.259)  0.201*** 
ART Medication 
-
0.030 0.073 (-0.174, 0.114)  -0.020  
-
0.080 0.070 (-0.218, 0.057)  -0.059  
-
0.069 0.071 (-0.209, 0.070)  -0.050 
Substance Abuse Diagnosis  0.059 0.055 (-0.049, 0.166)  0.053  0.074 0.054 (-0.032, 0.180)  0.071  0.055 0.054 (-0.053, 0.162)  0.053 
BMI  0.014 0.003 (0.008, 0.019)  0.245***  0.013 0.003 (0.007, 0.018)  0.236***  0.013 0.003 (0.007, 0.018)  0.240*** 
Viral Load 0.038 0.014 (0.011, 0.066)  0.134**  --- --- ---  ---  0.040 0.016 (0.009, 0.071)  0.146* 
CD4 Cell Count --- --- ---   ---   
-
0.012 0.007 (-0.025, 0.001)   -0.095   
-
0.005 0.007 (-0.019, 0.010)   -0.035 
Note: *p <0.05. ** p <0.01. ***p <0.001.               
Cardiac Risk Score1: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, and anti-hypertensive medication use.  
Cardiac Risk Score2: Defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-hypertensive medication use, total cholesterol, and HDL.  
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CHAPTER 3 - Cigarette smoking and metabolic syndrome in youth 





Background: Detectable viral load (VL) has been found to be associated with cardiovascular 
disease (CVD) and smoking among HIV-positive population. A recent study reported 20.4% of 
youth living with HIV (YLH) smoking cigarette daily or almost daily, and observed significance 
of cigarette smoking with higher mean log 10 VL. Metabolic changes leading to the development 
of atherosclerosis can start early in life, but are often undiagnosed in their early stages. Metabolic 
syndrome is a growing concern that may surpass smoking as one of the leading risk factors of 
CVD. We examined the association of smoking and metabolic syndrome with VL in YLH aged 
14-26y. 
Methods: The data for this study were drawn from the Adolescent Medicine Trials Network 154 
Cascade Monitoring Protocol. De-identified electronic health records of YLH who received care 
in 2016 were extracted from multidisciplinary adolescent HIV clinics across the United States. 
This study utilized a subsample of 398 YLH. Multivariable logistic regression was used to 
examine whether smoking and components of metabolic syndrome are related to a greater 
likelihood of high VL.  
Results: Our sample included a higher proportion of Black youth (76.8%) and males (69.6%) 
with mean age of 21y. Overall, 44.4% had a detectable VL, 26.9% were cigarette smokers based 
on ICD-10 diagnoses of tobacco dependence, and 27.6% met the criteria for metabolic 
syndrome. In bivariate analyses, among those who smoked cigarette compared to those who did 
not smoke, we observed a significantly greater proportion of patients with detectable VL (54.7% 
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vs. 40.6%; p < 0.05). Similarly, among those who had low HDL cholesterol compared to those 
who had ideal HDL, we observed a significantly greater proportion of patients with detectable 
VL (54.9% vs. 37.1%; p < 0.001). In multivariable analyses, after adjusting for demographic and 
clinical differences, the odds of having detectable VL among those who smoked cigarette is 
2.051 times that of those who did not smoke (AOR = 2.051; 95% CI = 1.101, 3.823; p < 0.05). 
However, no significant differences (p > 0.05) were observed in the components of metabolic 
syndrome on VL. 
Conclusions: We observed positive association between smoking and VL non-suppression, 
highlighting the importance of smoking cessation in viral suppression and in reducing the overall 
burden of CVD risk in YLH. Our findings of greater prevalence of metabolic syndrome suggests 
routine monitoring of metabolic risks in YLH. 
 
















Cardiovascular disease (CVD) is the leading cause of death in the United States (U.S.) 
and prevalence of high-risk individuals is prominent for non-Hispanic Black males.1 Despite 
advances in the identification of risk factors for CVD and the widespread use of evidence-based 
strategies to manage CVD, overall cardiovascular health is lowest in Black Americans than non-
Hispanic Whites, and CVD mortality is higher in Black Americans than White counterparts.2 
Since treatments for HIV have become more effective, research has shifted focus from the more 
acute symptoms onto the chronic comorbid conditions such as CVD.3,4  
According to the current guidelines, antiretroviral therapy (ART) is initiated immediately 
after diagnosis in youth and young adults5 however, youth and young adults are underrepresented 
in research on HIV and its connections to CVD. Cardiovascular health assessment practices and 
public health strategies for those young adults living with HIV and the younger populations at-
risk for HIV are few and far between and this lack of knowledge could pose significant problems 
as these generations grow older.    
Prior studies, including chapter 2 of the dissertation, have found that detectable viral load 
is associated with cardiovascular risk6,7 and smoking among HIV-positive populations in the 
U.S.8,9 Rates of tobacco use have been 40% of people with HIV10-13 and significantly more 
common compared to the general population.14-16 Among youth living with HIV (YLH), in 
particular, tobacco use has been reported to be 32.9-38.7% in two cross-sectional nationwide 
cohort studies recruited through the Adolescent Medicine Trials Network for HIV/AIDS 
Interventions (ATN).17,18 More recently, Gamarel and colleagues reported 20.4% of YLH 
smoking cigarettes daily or almost daily, and showed tobacco smoking predicting viral 
suppression, reinforcing the need for smoking cessation interventions and preventive services in 
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this population.19 Given that viral suppression fluctuates20 and tobacco use significantly predicts 
viral load (VL) levels, new screening tools and clinical and self-management approaches need to 
be explored and utilized, especially among YLH. 
Although smoking is one of the primary preventable causes of CVD, metabolic syndrome 
is a growing concern that may surpass smoking as one of the leading risk factors for CVD.21 
Metabolic syndrome is the clustering of any three of a group of five conditions that elevate risk 
of heart disease and diabetes: high blood pressure, high blood glucose, high triglycerides, low 
HDL cholesterol, and increased abdominal fat.22-24 The links among smoking, metabolic 
syndrome, and CVD in HIV-positive populations remain unclear. Although one study has found 
little association between cigarette smoking and metabolic risk factors among YLH,18 other 
studies have found tobacco use generally to be related to increased dyslipidemia, blood glucose 
processing, and metabolic syndrome, particularly with high triglycerides and low HDL 
cholesterol levels.25-29 In addition, although some studies have not found metabolic syndrome to 
be more prevalent in the HIV-positive population compared to the general population,30 other 
studies have shown that metabolic risk factors are indeed prevalent in the HIV-positive 
population,31-34 including YLH,35 and are independently associated with VL.32   
Being overweight and obese are themselves risk factors for CVD morbidity and 
mortality,36 and they are often associated with the development of CVD risk factors during 
adolescence.37 Data from the National Health and Nutrition Examination Survey provided the 
most recent national estimates from 2015-2016 on obesity and the prevalence of obesity was 
higher among U.S. adolescents aged 12-19 years (20.6%) compared with children aged 2-5 years 
(13.9%).38 Most importantly, adult adiposity is an established risk factor for developing adult 
CVD and there is evidence suggesting that overweight adolescents have a 40%-80% chance of 
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becoming overweight or obese adults.37 Despite the high prevalence of adolescent obesity and 
adult CVD, being overweight and obese has been studied less extensively within the HIV-
positive population.36 Although ART decreases the risk of HIV-specific morbidity and mortality, 
U.S.-based studies found that patients on ART experience an increase in body mass index 
(BMI),39,40 highlighting the importance of maintaining health body weight in adolescents 
initiating early ART.     
Given the increasing prevalence of obesity among American youth41 and that more than 
half of youth have been shown to have at least one CVD risk factor,42 there is an urgent need to 
better understand the relationship among metabolic risk factors, smoking, and CVD risk among 
YLH, a high-risk and underserved population. The current study leveraged the electronic health 
records (EHR) of a multi-site clinical sample of YLH in the U.S. to examine whether smoking 
and metabolic syndrome were associated with VL. 
Methods 
 
Study Design and Population 
 The data for this study were drawn from the ATN  Cascade Monitoring Study, one of the 
protocols of ATN’s Scale It Up initiative.43 De-identified EHR were requested from ten 
participating sites for the baseline year between January 1, 2016 and December 31, 2016 as 
described previously.44 To be included in these analyses, data on a patient’s age, race, ethnicity, 
gender, height, weight, CD4 cell count results, VL results, systolic blood pressure, cholesterol 
panel, blood pressure medications, ART medications, and the International Statistical 
Classification of Disease and Related Health Problems Tenth Revision (ICD-10) diagnosis codes 
for diabetes, cigarette smoking, alcohol and drugs were required. Because Brooklyn, Miami, 
Philadelphia, and San Diego did not provide gender, systolic blood pressure, and cholesterol 
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data, these four sites were excluded from further analyses (see Table 1). The Institutional Review 
Boards of both Florida State University and the City University of New York approved to 
conduct analyses of de-identified data.  
Measures 
Demographics. We defined age as a continuous variable in years as reported by site. 
Gender, race, and ethnicity definitions varied within a site’s data. These demographic variables 
were constructed as reported by site. For gender we constructed a binary variable of male vs. 
female. Race/ethnicity was categorized into Black, Latino, White, Hispanic or Other. Missing 
race for one patient was kept as missing data and removed from these analyses.  
HIV and immunologic biomarkers. Earliest date reported VL values in “copies/mL” by 
site were used. VL threshold detectability was coded as binary. Missing VL results for four 
patients were not included in these analyses. Based on the guidelines for the Use of 
Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we defined 
immunocompromised state as CD4 T lymphocyte cell count of less than or equal to 200.5,45 We 
created a binary variable of CD4 cell count with “baseline count ≤ 200” and “baseline count 
>200.” CD4 cell count, a measure of immune status, was missing for 13.8% (n = 55) of the 
sample and thus excluded from this analysis.   
ART medication. All prescribed HIV medications were coded into a dichotomous variable 
where 0 = no prescribed medication and 1 = at least one prescribed medication. Missing values 
were assumed to be the result of no prescription by doctors and were recoded into the category of 
non-ART medication.    
Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510, 
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drugs such as 
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amphetamines, cannabis, cocaine, hallucinogens, and opioids. A dichotomous variable was 
created for patients having any vs. no substance abuse.  Missing values were coded as no 
substance abuse.  
BMI. We used BMI, a measure of weight relative to height (kg/m2), as a proxy of 
adiposity. Tallest and earliest reported value for height and highest and earliest reported value for 
weight were used. Patients (n = 7) with missing values were removed from further analyses. We 
defined obesity as BMI ≥ 30 for patients who were between 21 and 26.46 For those who were 
between 14 and 20, obesity was defined as BMI for age and sex at or above the 95th percentile 
using the CDC growth chart.22,24,47  
Cigarette smoking. We used ICD-10 codes F17200 and F17210 for tobacco use. If these 
codes were missing, we pulled data from patient self-report such as current status and never 
smoked at each site. A dichotomous variable for smoking was created.  
 Hypertension medication. A dichotomous variable was created, including the presence of 
any site-reported prescriptions including amlodipine, enalapril, lisinopril, and spironolactone.  
 Hypertension. Since our target population was YLH, only systolic blood pressure as 
reported by site was used. Hypertension was defined as systolic blood pressure ≥ 130 mmHg or 
treatment with anti-hypertensive medication.22-24   
 Hyperglycemia. We used ICD-10 codes E10XX, E11XX or E13XX for diagnosis of 
diabetes. Patients without these ICD-10 diagnosis codes were given a missing value for diabetes 
and evaluated for predetermined criteria i.e. blood glucose HbA1c results > 6.0 mmol/L or 
fasting blood glucose of > 110 mg/dL or random blood glucose of > 180. We included diabetes 
diagnosis in addition to glucose measures for creating a dichotomous variable for hyperglycemia. 
We coded as hyperglycemia for patients reported to have diabetes or blood test results exceeded 
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predetermined criteria. Missing values for diabetes and those who did not meet predetermined 
criteria were coded as no hyperglycemia.  
 Triglycerides and HDL cholesterol. We defined hypertriglyceridemia as the fasting blood 
triglyceride levels ≥150 mg/dL.24 For low HDL cholesterol, < 45 mg/dL was used for boys and 
girls aged 19y or younger,48 while ≤ 40 mg/dL and <50 mg/dL were used for men and women 
aged 20y or older, respectively.48  
Metabolic syndrome. Metabolic syndrome comprises obesity, hypertriglyceridemia, low 
HDL cholesterol level, hypertension, and hyperglycemia.21 We constructed a categorical variable 
for metabolic syndrome with three categories: 0-1 component, 2 components, and 3 or more 
components.22-24 Patients with 3 or more components were considered to meet diagnostic criteria 
for metabolic syndrome.22-24   
Data Analysis 
For this study, we focused on a subset of patients (n = 398) from the baseline analytic 
sample of 813 EHRs collected in 2016 in order to incorporate routinely obtained laboratory data 
(glucose, triglycerides, and HDL cholesterol). To examine the prevalence of cigarette smoking 
and metabolic syndrome, we divided the study sample into two groups based on VL status. First, 
we performed a descriptive analysis of demographic and clinical characteristics of the sample. 
Second, we conducted bivariate analyses of the relationships along smoking, metabolic 
syndrome, and VL using chi-square and independent samples t-tests. Finally, we ran a series of 
three multivariable logistic regression models and examined the associations of smoking and 
components of metabolic syndrome with detectable VL as a dichotomous outcome variable. The 
first model was constructed to test the hypothesized positive association of smoking on 
detectable VL. The second model was constructed to test the hypothesized positive association of 
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metabolic syndrome on detectable VL. The third model was constructed to test the hypothesized 
positive associations of smoking and metabolic syndrome on detectable VL. Covariates included 
in the models were the required demographic variables – age, race/ethnicity, and gender. We also 
adjusted for the ue of ART medication, substance dependence, and CD4 cell count. All analyses 
were performed in IBM SPSS Statistics 25 and syntax files were developed to construct new 
variables and recode some variables based on the analytic design. The threshold for statistical 
significance was 0.05. 
Results 
Demographic and clinical characteristics of the analytic sample (n = 398) are displayed in 
Table 2. The mean age was 21y with a range of 14 to 26 years (SD = 2.7). The majority of the 
patients identified as Black (76.8%) followed by Other (10.6%), White (6.8%), and Latino 
(5.8%). More than half (69.6%) of the sample were male. The mean VL, a measure of ART 
adherence was 22,440 (SD = 93,965.4). Nearly half (44.4%) had a detectable VL. Among those 
with a detectable VL, 29.9% had > 1000 copies/mL. The mean CD4 cell count was 633 (SD = 
302.3). Among those with a CD4 cell count value available, 7.3% had a baseline count of ≤ 200 
indicating immunocompromised status.  
Among those sites with the required data for this study, Memphis had the largest sample 
size (n = 157; 39.4%). The mean BMI was 25 kg/m2 with a range of 4.8 to 69.5 (SD = 6.7) and 
the mean systolic blood pressure was 129 mmHg with a range of 92 to 180 (SD = 11.7). Of the 
398 YLH, 92.2% were currently prescribed ART; 15.6% were diagnosed with substance abuse; 
26.9% were smokers; 15.1% were obese; 52% had hypertension; 7.8% were hyperglycemic; 
15.4% had hypertriglyceridemia; and 40.7% had low HDL cholesterol level. The proportion of 
patients who met the criteria for each of the three categories of the metabolic syndrome is shown 
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in Figure 1. More than one-quarter (27.6%) of YLH had metabolic syndrome. Among male 
patients, 23.8% had two components of metabolic syndrome and 28.5% met the definition of 
metabolic syndrome. Among female patients, 26.4% had two components of metabolic 
syndrome and 25.6% met the definition of metabolic syndrome.  
Bivariate correlates across demographic and clinical variables 
Smoking vs. nonsmoking groups. The associations between demographic and clinical 
variables of interest are displayed in Table 3. The chi-square tests performed to compare the 
differences in detectable and undetectable VL for cigarette smoking status and CD4 cell count 
were statistically significant. Among those who smoked cigarette compared to those who did not 
smoke, we observed a significantly greater proportion of patients with detectable VL (54.7% vs. 
40.6%; p < 0.05). Among those who had CD4 cell count ≤ 200 compared to those who had CD4 
cell count > 200, we observed a significantly greater proportion of patients with detectable VL 
(84.0% vs. 41.0%; p < 0.001).  No significant differences (p > 0.05) were found in race/ethnicity, 
gender, ART medication, substance abuse diagnosis, hypertension medication, age, BMI, and 
systolic blood pressure.  
Clinical correlates of metabolic syndrome. The associations between the components of 
metabolic syndrome and VL are displayed in Table 4. Among those who had low HDL 
cholesterol compared to those who had ideal HDL, we observed a significantly greater 
proportion of patients with detectable VL (54.9% vs. 37.1%; p < 0.001). However, no significant 
differences (p > 0.05) were observed in other components of metabolic syndrome on VL when 
comparing patients who met the criteria for metabolic syndrome.  
Multivariable correlates of VL 
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 Cigarette smoking and metabolic syndrome. Multivariable logistic regression analysis of 
VL from demographic and clinical characteristics including smoking and metabolic syndrome is 
shown in a series of models in Table 5. Model 1 presents the association of cigarette smoking on 
VL. After adjusting for demographic and clinical differences, patients who smoked cigarette 
compared to those who did not smoke were significantly more likely to have detectable VL 
(AOR = 2.051; 95% CI = 1.101, 3.823; p < 0.05). This indicates that the odds of having 
detectable VL among those who smoked cigarette is 2.051 times that of those who did not 
smoke.  
Model 2 presents the association of the components of metabolic syndrome on VL. After 
adjusting for demographic and clinical differences, patients who had 2 components of metabolic 
syndrome compared to those who had 0-1 component of metabolic syndrome were marginally 
significant with detectable VL (AOR = 0.365; 95% CI = 0.818, 2.536; p = 0.052). Model 3 
presents the association of smoking and metabolic syndrome together on VL. After adjusting for 
demographic and clinical differences, patients who smoked cigarette compared to those who did 
not smoke were significantly more likely to have detectable VL (AOR = 2.038; 95% CL = 1.090, 
3.811; p < 0.05). This indicates that the odds of having detectable VL among those who smoked 
cigarette is 2.038 times that of those who did not smoke. Patients who had 2 components of 
metabolic syndrome was marginally significant with detectable VL (AOR = 0.360; 95% CI = 
0.811, 2.532; p = 0.056).  
Discussion 
The purpose of this study was to examine whether smoking and metabolic syndrome 
were associated with VL among YLH aged 14-26y in the U.S. In a clinic-based sample of 
predominantly Black YLH, nearly half (44.4%) had a detectable VL, 26.9% were smokers, and 
27.6% met the definition of metabolic syndrome. The estimated proportion achieving viral 
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suppression is lower than the U.S. estimates of 53.8% among persons aged 13-24 years.49 Our 
study had a lower prevalence of cigarette smoking than previously reported in two ATN cohort 
studies among YLH (32.9-38.7%).18 Prevalence estimates for the metabolic syndrome may vary 
based on the criteria used; nevertheless, our study found a higher prevalence of metabolic 
syndrome compared to a more recent study of 80 HIV-positive adolescents (aged 14.6-18y, 
10%).50  
Our findings support the hypothesis that smoking is positively associated with detectable 
VL after adjusting for potential confounding variables, highlighting the importance of linking 
smoking prevention and HIV care in routine clinical practice. These findings are consistent with 
a recent study of YLH engaged in HIV care in one of the ATN clinical sites or affiliates that also 
observed a significant association between tobacco use and decreased odds of sustained viral 
suppression.19 Although studies in adults provide evidence that cigarette smoking is associated 
with HIV prognosis,8,9,51 the potential mechanisms underlying the effect of smoking on HIV are 
unclear. As indicated by previous studies,51-53 smoking may cause or promote higher VL via 
various mechanisms, including oxidative stress and induction of the cytochrome P450 (CYP) 
pathway. More specifically, the CYP1A1-m1 polymorphism, which is associated with greater 
enzymatic activity, can increase VL through conversion of toxins found in cigarette smoke into 
DNA adducts, which may directly promote HIV-1 gene expression.51,53 Therefore, we 
hypothesized that higher oxidative stress may be a common mechanism underlying the 
pathophysiological process of increased odds of detectable VL being associated with smoking. 
However, the detailed mechanism on the potential biological effect of smoking on VL should be 
further studied.  
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After adjusting for potential confounding variables, we did not observe any statistically 
significant independent associations between the different components of metabolic syndrome 
and detectable VL among YLH. This finding points to increased prevalence of cardiometabolic 
risk factors and suggests clinical treatments are for the individual components, not metabolic 
syndrome as a whole. The framework of metabolic syndrome is a convenient tool used to 
understand the effects of insulin resistance on human physiology in populations studies24 but 
ultimately carries little clinical meaning beyond its individual components. Although 
pediatricians can use metabolic syndrome as an organizing framework, the focus for clinical 
screening and treatment should be on obesity, glucose abnormalities, hypertension, and 
dyslipidemia.24 Using EHR might be a useful strategy to incorporate screening tools and help 
medical providers to identify at-risk patients and provide guidance on prevention and 
management of metabolic dysfunction. This in turn could prevent or delay the onset of CVD.  
Atherosclerosis, the pathological process that involves inappropriate lipid metabolism 
and activation of the innate and adaptive immune systems in the arterial wall,54,55 accelerates 
during adolescence. CVD risk in youth aged 18 to 24 years is underestimated despite the high 
prevalence of CVD risk factors56-59 and early signs of atherosclerosis in this group.60,61 
Adolescence and young adulthood are critical developmental phases and can have a significant 
impact on cardiovascular health.62 Obesity has more than tripled in youth over the past 30 
years.41 CVD risk increases by 2-4% for each year a youth is obese.63 As many as 33% of 
adolescents are overweight,57 and this excess weight leads to dyslipidemia64 and increases in 
metabolic syndrome,65 diabetes,66 and CVD59 risk. CVD contributes to half of CVD deaths and is 
one of the leading causes of death in adolescents.67 More than half of youth in the U.S. have at 
least one CVD risk factor, and this directly affects cardiovascular health throughout the 
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lifespan.42 Adolescence is the key age because many CVD risk factors surface in adolescence67-70 
and track into adulthood.71 The AHA’s 2020 Strategic Impact Goals along with the National 
Heart, Lung, and Blood Institute’s (NHLBI) 2012 Expert Panel on Integrated Guidelines for 
Cardiovascular Health and Risk Reduction in Adolescents72 emphasize early prevention in 
adolescence42 to prevent the development of CVD later in life and help curtail the high costs. 
Our study sample had a disproportionately higher proportion of Black YLH and 
identified as male gender. Studies have demonstrated the high burden of CVD especially related 
to mortality in Black men and the high burden of HIV among Black youth in the U.S. A recent 
study analyzed the U.S. nationally representative data by calculating the CVD risk score 
developed in 2013 by the American Heart Association (AHA) and the American College of 
Cardiology and found that prevalence among non-Hispanic Black males increased significantly 
from 53% in 1999-2002 to 65.2% in 2011-2014 using the 7.5% 10-year risk cut off (p = 0.003).1 
The Centers for Disease Control and Prevention (CDC) reported continued trend of HIV 
infections among youth of color, Black and Latino representing 54% and 25% of new HIV 
diagnoses, respectively, compared to those who identified as White and Other, accounting for 
16% and 5% of new HIV diagnoses in 2016.73 Targeting HIV and CVD prevention, specifically 
in racial and ethnic minority populations of youth who are unaware of their risk of CVD, in a 
coordinated manner has important clinical implications. The earlier screening and treatment 
plans begin, the less risk these individuals have of developing metabolic syndrome, thus 
reducing their risk of CVD and mortality.   
  The AHA’s “seven metrics” have been created to educate the public on healthy lifestyle 
habits to ensure ideal cardiovascular health.74 These seven metrics define what cardiovascular 
health is and help us to prevent CVD in the future. The defining characteristics of cardiovascular 
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health include “non-smoking status or having quit more than 1 year ago, BMI < 25 kg/m2, ≥ 150 
minutes per week of physical activity, health dietary pattern (high in fruits and vegetables, fish, 
and fiber-rich whole grains, low in sodium and sugar-sweetened beverages), total cholesterol < 
200 mg/dL, blood pressure < 120/80 mm/Hg, and fasting blood glucose < 100 mg/dL.”75 To 
summarize, a healthy lifestyle means a healthy heart. By focusing on decreasing health 
inequalities linked to impoverished areas and social minorities as well as defining easy steps to 
educate those who otherwise might have made unhealthy choices will, through prevention, 
decrease the strain that CVD has on the health system and on public health in general. However, 
there is an increased risk of CVD within the HIV-positive community that needs to be addressed. 
Although these “seven metrics” can be helpful preventing CVD in HIV-positive individuals in 
the same way as they are in the general population, the metrics doesn’t cover risks that only 
pertain to those who live with HIV and can’t be prevented, such as the side effects of ART and 
the impact HIV itself has on the cardiovascular health. The lack of studies on the “seven metrics” 
for cardiovascular health among YLH is a problem and further research on this link must be 
investigated.    
 This study has some limitations. First, the study design was cross-sectional so no 
causality could be inferred. Our clinic-based sample may also limit the generalizability of our 
findings to the entire YLH population in the U.S. Second, the lack of smoking data within the 
EHR on how much (number of packs per day) and how long (number of years) limited the study 
from assessing the association of quantity and duration of smoking with VL. A large multicenter 
prospective study with long-term follow-up should be implemented in the future to identify 
trajectories of smoking over time. Third, the cross-sectional study design does not provide 
evidence regarding the potential mechanism of the association of smoking and 2 components of 
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metabolic syndrome on VL. Future research needs to focus on the pathways and test the 
mediation effects of higher oxidative stress as the pathophysiological process of higher plasma 
VL associated with smoking. Fourth, the present study did not examine the combined effect of 
smoking and metabolic syndrome on VL. Future investigation is needed to further assess the 
synergistic effect of smoking and the components of metabolic syndrome on VL. Fifth, we used 
BMI as the metric to define obesity clinically because of lack of data on body composition and 
body fat distribution, which are more precise indicators of metabolic and cardiovascular risk. 
Finally, although regression was used for adjusting confounders, residual confounders cannot be 
avoided and it can bias the association in any direction (towards or away from the null). Despite 
these limitations, our results provide an opportunity to capitalize on the potential long-term 
benefits of routinely collected EHR data for public health surveillance.  
 The present study indicates that cigarette smoking is positively associated with increased 
odds of having detectable VL in YLH, while the presence of different components of metabolic 
syndrome was not observed to be significantly associated, and these observations supplement the 
existing knowledge on the relationship among smoking, metabolic syndrome, and VL. 
Furthermore, this study highlights the need for more research in diverse population cohorts of 
YLH in order to gain additional insights into any disparities in the relationship of HIV with 
cardiometabolic risk factors in Black YLH compared with other racial/ethnic groups. Overall, 
more routine metabolic monitoring is key to improve the cardiovascular health of YLH. Smoking 
prevention intervention platform integrated with EHR as well as effective implementation of 
evidence-based guidelines could improve cardiovascular health and lower cardiometabolic risk 
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Table 1. Data Sources 
City n  % 
Baltimore 72 18.1 
Birmingham 44 11.1 
Los Angeles 67 16.8 
Memphis 157 39.4 
Tampa 54 13.6 
Washington DC 4 1.0 
Total 398 100.0 
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Table 2. Demographic and Clinical Characteristics of the Sample (N = 398) 
  n %  
Race/Ethnicity (n = 397)    
Black 305 76.8  
Latino 23 5.8  
White 27 6.8  
Other 42 10.6  
Gender     
Male 277 69.6  
Female 121 30.4  
ART Medication     
Currently on ART medication  367 92.2  
Not reportedly on ART medication 31 7.8  
Viral Load (n = 394)    
Detectable VL 175 44.4  
Undetectable VL 219 55.6  
CD4 Cell Count (n = 343)    
Baseline count ≤ 200 25 7.3  
Baseline count > 200 318 92.7  
Substance Abuse Diagnosis    
Diagnosed with substance abuse 62 15.6  
Not diagnosed with substance abuse 336 84.4  
Cigarette Smoking Status    
Smoking 107 26.9  
Nonsmoking 291 73.1  
Hypertension Medication    
Currently on hypertension medication 4 1.0  
Not reportedly on hypertension medication 394 99.0  
Obesity    
Yes 60 15.1  
No 338 84.9  
Hypertension    
Yes 207 52.0  
No 191 48.0  
Hypertriglyceridemia (n = 395)    
Yes 61 15.4  
No 334 84.6  
Low HDL Cholesterol    
Yes 162 40.7  
No 236 59.3  
Hyperglycemia    
Yes 31 7.8  
No 367 92.2  
    
 M SD  
Age (Range: 14 - 26; Mdn. = 21) 21 2.7  
BMI (Range: 4.8 - 69.5; Mdn. = 23.5) 26 7.1  
Systolic Blood Pressure (Range: 92 - 180; Mdn. = 130)  129 11.7  
ART antiretroviral therapy, BMI body mass index, HDL high-density lipoprotein  
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Figure 1. Metabolic syndrome among a clinic-based sample of YLH aged 14-26 in the 
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Table 3. Bivariate Association with Cigarette Smoking Status and VL 
  
Total 
Sample   Detectable VL   Undetectable VL       
 N = 394  n = 175  n = 219  Test Statistics 
  n %  n %  n %  df χ² 
Race/Ethnicity (n = 393)            
Black 301 76.6  142 81.6  159 72.6  3 5.418 
Latino 23 5.9  10 5.7  13 5.9    
White 27 6.9  8 4.6  19 8.7    
Other 42 10.7  14 8.0  28 12.8    
Gender             
Male 275 69.8  124 70.9  151 68.9  1 0.168 
Female 119 30.2  51 29.1  68 31.1    
ART Medication             
Currently on ART medication  363 92.1  159 90.9  204 93.2  1 0.706 
Not reportedly on ART medication 31 7.9  16 9.1  15 6.8    
Cigarette Smoking Status            
Smoking 106 26.9  58 33.1  48 21.9  1 6.232* 
Nonsmoking 288 73.1  117 66.9  171 78.1    
CD4 Cell Count (n = 340)            
Baseline count ≤ 200 25 7.4  21 14  4 2.1  1 17.409*** 
Baseline count > 200 315 92.6  129 86  186 97.9    
Substance Abuse Diagnosis            
Diagnosed with substance abuse 62 15.7  30 17.1  32 14.6  1 0.47 
Not diagnosed with substance abuse 332 84.3  145 82.9  187 85.4    
Hypertension Medication            
Currently on hypertension medication 4 1.0  2 1.1  2 0.9  1 0.051 
Not reportedly on hypertension medication 390 99.0  173 98.9  217 99.1    
            
 M SD  M SD  M SD  df F 
Age  21 2.7  21 2.7  21 2.6  392 1.250 
BMI 25.6 7.1  25.4 7.4  25.7 6.9  392 0.033 
Systolic Blood Pressure  129 11.7   130 12.3   129 11.1   392 0.248 
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.            
ART antiretroviral therapy, BMI body mass index, VL viral load          





Table 4. Bivariate Association with Metabolic Syndrome and VL 
  Total Sample   Detectable VL   Undetectable VL       
 N = 394  n = 175  n = 219  Test Statistics 
  n %  n %  n %  df χ² 
Obesity            
Yes 60 15.2  21 12.0  39 17.8  1 2.542 
No 334 84.8  154 88.0  180 82.2    
Hypertension            
Yes 207 52.5  95 54.3  112 51.1  1 0.386 
No 187 47.5  80 45.7  107 48.9    
Hypertriglyceridemia (n = 391)            
Yes 61 15.6  24 13.9  37 17.0  1 0.704 
No 330 84.4  149 86.1  181 83.0    
Low HDL Cholesterol            
Yes 162 41.1  89 50.9  73 33.3  1 12.338*** 
No 232 58.9  86 49.1  146 66.7    
Hyperglycemia            
Yes 31 7.9  17 9.7  14 6.4  1 1.480 
No 363 92.1  158 90.3  205 93.6    
Metabolic Syndrome            
0-1 Components indicated 187 47.5  75 42.9  112 51.1  2 3.452 
2 Components indicated 97 24.6  50 28.6  47 21.5    
≥3 Components indicated 110 27.9   50 28.6   60 27.4       
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.           
HDL high-density lipoprotein, VL viral load           
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Table 5. Multivariable Logistic Regression Models by VL 
  
Model 1: Smoking with 
Detectable VL    
Model 2: MetSyn with 
Detectable VL 
 
Model 3: Smoking and MetSyn 
with Detectable VL  
  B 95% CI AOR  B 95% CI AOR  B 95% CI AOR 
Age -0.025 (0.881, 1.080) 0.975  0.022 (0.930, 1.124) 1.022  -0.020 (0.885, 1.086) 0.980 
Race/Ethnicity (Ref: White)            
Black 0.612 (0.696, 4.886) 1.844  0.633 (0.721, 4.919) 1.883  0.647 (0.718, 5.084) 1.911 
Latino 0.345 (0.318, 6.268) 1.411  0.581 (0.409, 7.812) 1.79  0.468 (0.358, 7.120) 1.597 
Other -0.220 (0.237, 2.716) 0.803  0.004 (0.307, 3.280) 1.004  -0.189 (0.245, 2.803) 0.828 
Gender (Ref: Female)            
Male -0.092 (0.546, 1.523) 0.912  -0.080 (0.552, 1.545) 0.923  -0.090 (0.545, 1.532) 0.914 
ART Medication (Ref: Not on ART)            
Currently on ART medication  -0.522 (0.264, 1.334) 0.593  -0.613 (0.241, 1.215) 0.542  -0.507 (0.268, 1.356) 0.602 
Substance Abuse Diagnosis (Ref: No)            
Diagnosed with substance abuse -0.066 (0.490, 1.788) 0.937  0.138 (0.614, 2.146) 1.148  -0.050 (0.496, 1.824) 0.951 
Cigarette Smoking Status (Ref: Nonsmoking)            
Smoking 0.719 (1.101, 3.823) 2.051*  --- --- ---  0.712 (1.090, 3.811) 2.038* 
CD4 Cell Count  -0.223 (0.733, 0.872) 0.800***  -0.226 (0.731, 0.871) 0.798***  -0.227 (0.730, 0.870) 0.797*** 
Metabolic Syndrome (Ref: 0-1 Components)            
2 Components indicated --- --- ---  0.365 (0.818, 2.536) 1.440  0.360 (0.811, 2.532) 1.433 
≥3 Components indicated --- --- ---   0.554 (0.996, 3.039) 1.740   0.551 (0.987, 3.047) 1.734 
Note: *p < 0.05. ** p < 0.01. ***p < 0.001.            
ART antiretroviral therapy, VL viral load, MetSyn Metabolic Syndrome          
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CHAPTER 4 - Focus on single tablet regimen and lipid profile 




Background: HIV itself and antiretroviral therapy (ART) are known to contribute to the 
elevated risk of cardiovascular disease (CVD), including lipid abnormalities. Although early 
treatment with ART might reduce the negative effect of HIV on overall cardiovascular risk, 
many HIV medications have intrinsic toxicity profiles. Single tablet regimens (STRs) have 
become an integral part of HIV management. STR has the potential for improved adherence due 
to a lower pill burden, especially among youth living with HIV (YLH). The current study 
examined whether detectable VL and STR contribute to lipid abnormalities among YLH aged 
14-26y.    
Methods: We analyzed a sub-sample of 398 de-identified electronic health records of YLH 
extracted from multidisciplinary adolescent HIV clinics for the Adolescent Medicine Trials 
Network 154 Cascade Monitoring Protocol. We conducted bivariate and multivariable logistic 
regression analyses to examine differences in lipid abnormalities by VL and STR status.  
Results: Our sample included a higher proportion of Black (305, 76.8%) and males (69.6%) with 
mean age of 21y. Nearly half (44.4%) of YLH had a detectable VL and a majority of YLH were 
currently on ART. Nearly half (40.7%) of YLH did not meet the ideal range of HDL and 28.5% 
were in the clinically high range of LDL cholesterol. Similarly, 15.1% of YLH had high total 
cholesterol and 15.4% had high triglycerides. Among those who were currently prescribed STR, 
we observed a significantly lower proportion of YLH with high total cholesterol compared to 
those who were not on STR (14.2% vs. 33.3%; p < 0.05). Among those with detectable VL, we 
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observed a significantly higher proportion of YLH with low HDL compared to those without 
detectable VL (50.9% vs. 33.3%; p < 0.001). After adjusting for demographic and clinical 
covariates, treatment with STR was associated with significantly decreased odds of having high 
total cholesterol (AOR = 0.14; 95% CI = 0.03, 0.59; p < 0.01) and low HDL (AOR = 0.17, 95% 
CI = 0.03, 0.88; p < 0.05) compared to those not on STR. On the other hand, having a detectable 
VL significantly increased the odds of having low HDL compared to those without detectable 
VL (AOR = 2.07; 95% CI = 1.24, 3.47; p < 0.01). 
Conclusions: Detectable VL was associated with significantly increased odds of having low 
HDL, while the use of STR was associated with a more favorable lipid profile. Our findings 
suggest the adoption of STR may be an important strategy to lower VL and protect YLH against 
metabolic dysfunction associated with HIV. 
 














HIV infection itself and antiretroviral therapy (ART) are both known to contribute to the 
elevated risk of cardiovascular disease (CVD), including lipid abnormalities in the HIV-positive 
population.1-4 Lipid abnormalities are common in patients with HIV who are receiving ART.1,5,6 
Persistent inflammation and chronic immune activation contribute substantially to lipid 
abnormalities, resulting in premature CVD despite viral suppression.6 Lipid abnormalities is not 
an adult-only health concern, especially in the HIV-positive population. Youth living with HIV 
(YLH) can be at risk of developing lipid abnormalities. However, there are currently no specific, 
evidence-based recommendations for managing lipid levels in HIV-positive youth and 
adolescents.  
According to the National Heart, Lung, and Blood Institute (NHLBI) guidelines for youth 
and young adults, screening is recommended at ages 9 to 11y and is repeated every 5 years.7 
Despite the lack of specific national guidelines, because of the association of ART with lipid 
abnormalities, those with HIV are recommended to undergo lipid testing routinely throughout 
care,1 however, this is not currently practiced routinely in youth and the recommendation did not 
specifically mention youth. The HIV Medicine Association of the Infectious Disease Society of 
America and the guidelines on antiretroviral management of patients with HIV infection from 
the U.S. Department of Health and Human Services recommend screening for lipid abnormalities 
at baseline, prior to initiating ART, within one to three months after starting a new regimen and 
every 6 to 12 months thereafter.8,9  
Screening for lipid abnormalities in younger adults is an area of significant uncertainty as 
there is no evidence that it leads to improved patient outcomes and there are potentially 
substantial costs in routine screening the entire population.10,11 However, HIV-positive youth 
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with detectable viral load (VL) and currently taking ART could benefit from routine screening 
for lipid abnormalities, especially for identifying those at increased risk for CVD and receiving 
interventions aimed at reducing cardiovascular risk.1 HIV itself has been shown to alter lipid 
profile but the presence of traditional cardiovascular risk factors, such as hypertension and 
cigarette smoking, among this patient population increases substantially the risk of CVD.2,4 
While early treatment with ART might reduce the negative effect of HIV on overall 
cardiovascular risk, many HIV medications have intrinsic toxicity profiles contributing to lipid 
abnormalities.2,4 For the HIV-positive population, this suggests the importance of analyzing the 
impact of HIV medications on lipid profiles. With the use of newer antiretroviral agents, it is also 
prudent to distinguish between agents within each class to help HIV care providers make 
decisions on what medications to prescribe or when to change an HIV regimen in the context of 
overall health.   
Single tablet regimens (STRs) are one-pill-a-day and have become an integral part of 
initial ART for the management of HIV.12 A STR is a fixed-dose combination of two or more 
HIV drugs from the same or different classes.12-14 The single, one-dose pill has the potential for 
improved adherence due to a lower pill burden,12 especially among YLH. As such, STRs are 
currently the most preferred prescription choices for HIV treatment in the US.13 The first STR 
approved by the Food and Drug Administration (FDA) in 2006, Atripla, represents a viable 
option whether beginning in a naïve patient or switching HIV regimens.12,14,15 Other commonly 
prescribed STRs include Complera, Stribild, and Triumeq.12 Atripla and Complera consist of one 
different non-nucleoside reverse transcriptase inhibitor (NNRTI) and two of the same nucleoside 
reverse transcriptase inhibitor (NRTI) agents.12,14 Tenofovir and emtricitabine are the first-line 
NRTIs that do not have an adverse effect on lipid profiles.2 In a trial of treatment-naïve patients 
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initiating the newer formulation of tenofovir, tenofovir alafenamide vs. tenofovir disoproxil 
fumarate, as one of the four agents of the STR, the ratio of total cholesterol to high-density 
lipoprotein (HDL) remained unchanged for both regimens.16,17 It is not known if these findings 
extend to youth. 
Although NNRTIs are associated with an increase in low-density lipoprotein (LDL) 
cholesterol and total cholesterol levels, this increase is counterbalanced by an increase in HDL 
cholesterol during treatment with NNRTI therapy.18 Rilpivirine, which is available as a 
component of Complera, appears to have favorable overall lipid profile when compared with 
efavirenz, a component of Atripla.19-21 In two large trials of ART-naïve HIV-positive participants 
initiating an NNRTI-based regimen, efavirenz increased total cholesterol, HDL cholesterol, LDL 
cholesterol, and triglyceride levels when compared with rilpivirine.20,21 Since increases in the 
HDL cholesterol fraction are considered cardioprotective and that HDL was significantly 
increased among those receiving efavirenz, there was no difference in changes of the total 
cholesterol/HDL cholesterol ratio between the two treatments.2,20,21  
Elsewhere, prior studies show an association between protease inhibitors (PIs) and 
cardiovascular events.22-24 The recommended PIs that require a low dose of ritonavir for boosting 
darunavir have been associated with lipid abnormalities.25 All agents in the integrase inhibitor 
(II) class are associated with favorable lipid profiles.2 Overall, most of the agents available as a 
component of STR have been shown to have a favorable lipid profile, at least in adult patients. 
The current study was undertaken to examine the associations of VL status and STR treatment 





Study Design and Population 
 The data for this paper were drawn from one of the protocols of the Adolescent Medicine 
Trials Network (ATN) Scale It Up initiative, the ATN Cascade Monitoring Study.26 De-
identified electronic health records (EHR) were requested from ten participating sites for the 
baseline year between January 1, 2016 and December 31, 2016 as described previously.27 To be 
included in these analyses, data on a patient’s age, race, ethnicity, gender, height, weight, CD4 
cell count results, VL results, systolic blood pressure, cholesterol panel, blood pressure 
medications, ART medications, and the International Statistical Classification of Disease and 
Related Health Problems Tenth Revision (ICD-10) diagnosis codes for cigarette smoking, 
alcohol and drugs were required. Because Brooklyn, Miami, Philadelphia, and San Diego did not 
provide gender, systolic blood pressure, and cholesterol data, these 4 sites were excluded from 
further analyses (see Table 1). The Institutional Review Boards of both Florida State University 
and the City University of New York approved to conduct analyses of de-identified data.  
Measures 
Demographics. We defined age as a continuous variable in years as reported by site. 
Gender, race, and ethnicity definitions varied within a site’s data. These demographic variables 
were constructed as reported by site. For gender we constructed a binary variable of male vs. 
female. Race/ethnicity variable was categorized into Black, Latino, White, Hispanic, or Other. 
Missing race for one patient was kept as missing data and removed from these analyses.  
HIV and immunologic biomarkers. Earliest date reported VL values in “copies/mL” by 
site were used. VL threshold detectability was coded as binary. Missing VL results for four 
patients were not included in these analyses. Based on the guidelines for the Use of 
Antiretroviral Agents in HIV-1 Infected Adults and Adolescents, we defined 
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immunocompromised as CD4 T lymphocyte cell count of less than or equal to 200.28,29 We 
created a binary variable of CD4 cell count with “baseline count ≤ 200” and “baseline count 
>200.” Missing CD4 results for 13.8% (n = 55) of the sample were not included in these 
analyses.  
ART medication. All prescribed HIV medications were coded into a dichotomous 
variable. Missing values were assumed to be the result of no prescription by doctors and were 
recoded into the category of non-ART medication.    
Substance abuse diagnosis: We used ICD-10 codes F1010, F1210, F1220, F1290, F1510, 
F1511, F1520, F1590, F17200, F17210, F1910, and F1920 to identify alcohol and drugs such as 
amphetamines, cannabis, cocaine, hallucinogens, and opioids. A dichotomous variable was 
created for patients having any vs. no substance abuse. Missing values were coded as no 
substance abuse.  
Body mass index (BMI). BMI, a measure of weight relative to height (kg/m2) was used to 
serve as a proxy of adiposity. Tallest and earliest reported value for height and highest and 
earliest reported value for weight were used. Patients (n = 7) with missing values were removed 
from further analyses.  
Systolic blood pressure. Since our target population was YLH, only systolic blood 
pressure as reported by site was used to construct a numeric variable.  
Cigarette smoking. We used ICD-10 codes F17200 and F17210 for tobacco use. If these 
codes were missing, we pulled data from patient self-report such as current status and never 
smoked at each site. A dichotomous variable for smoking was created.  
Triglycerides and HDL cholesterol. We defined hypertriglyceridemia as the fasting 
triglyceride levels ≥ 150 mg/dL.30 For low HDL cholesterol, < 45 mg/dL was used for males and 
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females aged 19y or younger,7 while ≤ 40 mg/dL and < 50 mg/dL were used for men and women 
aged 20y or older, respectively.7  
Total cholesterol and LDL cholesterol. For high total cholesterol, ≥ 170 mg/dL was used 
for males and females aged 19y or younger, while > 200 mg/dL was used for men and women 
aged 20y or older, respectively.7 We defined high LDL cholesterol as the fasting blood LDL 
levels ≥ 100 mg/dL.7   
ART prescribed categories. The extracted medication files received from the sites were 
initially coded into five types of ART. Combinations of three or more HIV medicines from at 
least two different HIV drug classes were coded as STR as displayed in Table 2. The remaining 
HIV medicines were coded as NRTI, NNRTI, PI, and II. The earliest visit date with the first 
ART prescribed status was used to categorize HIV treatment regimen for the baseline medication 
data. We then created a patient-level dataset with a dichotomous indicator for every medication 
code. A count variable was also created for the number of different drug classes prescribed per 
patient.     
Data Analysis 
For this study, we focused on a subset of patients (n = 398) from the baseline analytic 
sample of 813 health records collected in 2016 in order to incorporate HIV treatment regimen 
and lipid profile. First, we performed a descriptive analysis of demographic and clinical 
characteristics of the sample documented in the EHR system across the U.S. Second, we created 
a dichotomous indicator for each lipid and conducted bivariate analyses using all four lipid 
indicators individually as an outcome as opposed to using a categorial variable of lipid profile 
with four groups. We analyzed our results across lipid outcomes by STR and VL status in the 
bivariate analyses. Chi-square tests of independence were used for categorical variables and 
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independent samples t-tests were performed for continuous variables. Third, we ran a series of 
three multivariable logistic regression models with total cholesterol as a dichotomous outcome 
variable. The first model was constructed to determine whether HIV-positive youth with 
detectable VL are more likely to have high total cholesterol as compared to those with 
undetectable VL. The second model was constructed to examine whether STR was 
independently associated with total cholesterol level in YLH. The third model was constructed to 
examine the combined effect of detectable VL and STR with total cholesterol level. Covariates 
included demographic variables (age, race/ethnicity, and gender) and BMI, systolic blood 
pressure, substance dependence, cigarette smoking, and CD4 cell count. Adjusted odds ratios 
(AOR) from the models are presented for the odds of classfication with high total cholesterol 
relative to normal total cholesterol as the reference group.  
Finally, we repeated the series of three multivariable logistic regression models with low 
HDL cholesterol as the outcome variable and the same independent variables and covariates. For 
our lipid models, we performed multivariable analyses for the total cholesterol and HDL only 
since these are the two predicting factors included in the Framingham Risk Score and the other 
two lipids were not observed to be statistically significant in the bivariate comparisons. All 
analyses were performed in IBM SPSS Statistics 25 and syntax files were developed to construct 
new variables and recode some variables based on the analytic design. The threshold for 
statistical significance was 0.05. 
Results 
Demographic and clinical characteristics of the analytic sample (n = 398) are displayed in 
Table 3. The mean age was 21y with a range of 14 to 26 years (SD = 2.7). The majority of the 
patients identified as Black (76.8%) followed by Other (10.6%), White (6.8%), and Latino 
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(5.8%). More than half (69.6%) of the sample were male. The mean VL, a measure of ART 
adherence was 22440 (SD = 93965.4). Nearly half (44.4%) had a detectable VL. Among those 
with a detectable VL, 29.9% had > 1000 copies/mL. The mean CD4 cell count was 633 (SD = 
302.3). Among those with a CD4 cell count value available, 7.3% had a baseline count of ≤ 200 
indicating immunocompromised status.  
Among those sites with the required data for this study, Memphis had the largest sample 
size (n = 157; 39.4%). The mean BMI was 25 kg/m2 with a range of 4.8 to 69.5 (SD = 6.7) and 
the mean systolic blood pressure was 129 mmHg with a range of 92 to 180 (SD = 11.7). Of the 
398 YLH, 15.6% were diagnosed with substance abuse and 26.9% had ICD-10 codes for tobacco 
use. Of those with cholesterol data, 15.1% had high total cholesterol; 28.1% had high LDL 
cholesterol; 15.4% had hypertriglyceridemia; and 40.7% had low HDL cholesterol level. The 
majority of patients 92.2% (n = 367) were currently taking ART. Of the active ART users, 95.9% 
were prescribed STR on the earliest visit date.  
Bivariate correlates across lipid outcomes 
STR vs. non-STR groups. Examining the cholesterol outcomes in STR vs. non-STR 
groups, several general trends emerged that are displayed in Table 4. First, we performed chi-
square tests to compare the differences across total cholesterol outcomes by STR group. Among 
those who were currently prescribed STR compared to those not on STR, we observed a 
significantly lower proportion of patients with high total cholesterol (14.2% vs. 33.3%; p < 0.05). 
Second, we performed the chi-square tests to compare the differences across high LDL 
cholesterol outcomes by STR group. Among those who were currently prescribed STR compared 
to those not on STR, no significant differences (p > 0.05) were observed with high LDL 
cholesterol. Third, we performed the chi-square tests to compare the differences across HDL 
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cholesterol outcomes by STR group. Among those who were currently prescribed STR compared 
to those not on STR, no significant differences (p > 0.05) were observed with low HDL 
cholesterol. Fourth, we performed the chi-square tests to compare the differences across 
hypertriglyceridemia outcomes by STR group. Among those who were currently prescribed STR 
compared to those not on STR, no significant differences (p > 0.05) were observed with 
hypertriglyceridemia.  
Detectable vs. undetectable VL. Examining the cholesterol outcomes by VL status, we 
observed a significant difference only across HDL cholesterol outcomes as displayed in Table 4. 
Among those who had detectable VL compared to those who had undetectable VL, we observed 
a significantly higher proportion of patients with low HDL cholesterol (50.9% vs. 33.3%; p < 
0.001). However, no significant differences (p > 0.05) were observed in other cholesterol 
outcomes when comparing patients who had detectable VL with those who had undetectable VL. 
Refer to Table 4 for demographic and other ART differences across cholesterol outcomes.   
Multivariable analyses across total cholesterol and HDL cholesterol outcomes 
 STR vs. non-STR groups. Multivariable logistic regression across total cholesterol and 
HDL outcomes by STR group are displayed in Table 5 and Table 6. Model 1A presents the 
association of STR alone with high total cholesterol. After adjusting for demographic and 
clinical differences, treatment with STR significantly decreased the odds of the patient having 
high total cholesterol compared to those not on STR (AOR = 0.16; 95% CI = 0.04; 0.65; p < 
0.05). Model 2A presents the association of STR alone with low HDL cholesterol. After 
adjusting for demographic and clinical differences, treatment with STR significantly decreased 
the odds of the patient having low HDL cholesterol compared to those not on STR (AOR = 0.16; 
95% CI = 0.03, 0.83; p < 0.05). 
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 Detectable vs. undetectable VL. Multivariable logistic regression across total cholesterol 
and HDL outcomes by VL status are displayed in Table 5 and Table 6. Model 1B presents the 
association of detectable VL alone with high total cholesterol. After adjusting for demographic 
and clinical differences, having a detectable VL did not significantly increased the odds of the 
patient having high total cholesterol compared to those without detectable VL (p > 0.05). Model 
2B presents the association of detectable VL alone with low HDL cholesterol. After adjusting for 
demographic and clinical differences, having a detectable VL significantly increased the odds of 
the patient having low HDL cholesterol compared to those without detectable VL (AOR = 1.97; 
95% CI = 1.21, 3.21; p < 0.01). 
STR and detectable VL. Multivariable logistic regression across total cholesterol and 
HDL outcomes by STR and detectable VL together are displayed in Table 5 and Table 6. Model 
1C presents the association of STR and detectable VL together with high total cholesterol. After 
adjusting for demographic and clinical differences, treatment with STR significantly decreased 
the odds of the patient having high total cholesterol compared to those not on STR (AOR = 0.14; 
95% CI = 0.03, 0.59; p < 0.01) whereas detectable VL was not found to be independently 
associated with high total cholesterol. Model 2C presents the association of STR and detectable 
VL together with low HDL cholesterol. After adjusting for demographic and clinical differences, 
treatment with STR significantly decreased the odds of the patient having low HDL cholesterol 
compared to those not on STR (AOR = 0.17; 95% CI = 0.03, 0.88; p < 0.05). Similarly, having a 
detectable VL significantly increased the odds of the patient having low HDL cholesterol 
compared to those without detectable VL (AOR = 2.07; 95% CI = 1.24, 3.47; p < 0.01). Refer to 
Table 5 and Table 6 for age, gender, systolic BP, and CD4 differences across cholesterol 




The purpose of this study was to examine whether STR regimen and detectable VL were 
associated with lipid outcomes in U.S.-based YLH aged 14-26y treated at multidisciplinary 
adolescent HIV care settings. Our study is the first to report estimated prevalence of lipid 
abnormalities in YLH and had a relatively healthy sample who were predominantly on STR. We 
found that nearly half (40.7%) of YLH did not meet the ideal range of HDL cholesterol and 
28.5% were in the clinically high range of LDL cholesterol. Similarly, 15.1% of the sample had 
high total cholesterol and 15.4% had high triglycerides. These results are consistent with findings 
in the National Health and Nutrition Examination Surveys (NHANES) study which analyzed 
nationally representative data from more than 26,000 children and adolescents and observed 
trends for levels of triglycerides and LDL cholesterol from 1999 to 2016, but only 47% to 50% 
of U.S. youth had all lipids at ideal levels and 19% to 25% had at least one adverse level.31 The 
NHANES study analyzed U.S. population-weighted data for youth aged 6 to 19 years and did not 
include HIV status. This study helps to fill this gap and shows that EHR data could be leveraged 
more routinely to examine CVD risk factors in special populations such as YLH.   
Our findings supporting the hypothesis that patients on STR have a higher likelihood of 
not experiencing lipid dysfunction is consistent with previous studies targeting adults.2,16,17,19-21 
However, with the newer formulation of STR, EHR data can be used to conduct longitudinal 
studies and distinguish between agents within each single tablet regimen and their impact on 
lipid profiles. These data can be efficiently collected and analyzed to generate prediction models 
to identify HIV-positive youth at risk for CVD due to lipid abnormalities. With the use of 
longitudinal data, future research can estimate the differences in lipid levels at multiple time 
points and examine percent change from baseline to promote STRs with the most favorable lipid 
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profile for YLH. In particular, because the use of some protease inhibitors have been associated  
with changes in lipid levels and are included as a component of STR,2 lipids should be evaluated 
before and subsequent to protease inhibitor initiation.  
Our findings also support the hypothesis that patients with detectable VL are more likely 
to have low HDL cholesterol. The mechanism for these observations is unclear but it is likely to 
be related to impaired cholesterol synthesis. Recent studies have focused on measuring plasma 
HDL functionality using a cholesterol efflux (CE) capacity assay, an emerging cell-based assay 
that predicts CVD events in the general population and could be used as a biomarker of 
atherosclerosis.32,33 In the field of HIV, one postulated mechanism links HIV inhibition of 
cholesterol efflux from accumulation of lipids within macrophages.2 A recent study observed 
patients with detectable VL revealed impaired CE capacity compared with healthy individuals 
and that immune status secondary to HIV progression and exposure influence plasma HDL-CE 
capacity.33  
The present study showing VL non-suppression linked with lipid abnormalities is new 
and has two important clinical implications for YLH. The last decade has seen a burgeoning 
evidence indicating that HIV infection itself is a risk factor for coronary heart disease and that 
HIV itself has been shown to increase lipogenesis in the liver and to alter the lipid profile.2 Our 
finding suggests VL monitoring is critical to ensure VL suppression in YLH because suppression 
of HIV itself may be cardioprotective, possibly by reducing proinflammatory cytokines (e.g., 
interleukin-6) that play a role in arterial inflammation.34,35 However, performing traditional 
serological testing requires youth to schedule an appointment either with their primary care 
provider or a laboratory to extract the serum from blood specimens. Utilizing technology and 
promoting self-management (e.g., using home-based dried blood spot as a VL monitoring 
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device) may be beneficial but requires more implementation science research. In addition, our 
finding also suggests screening earlier for lipid abnormalities and follow-up lipid screening, 
especially for HIV-positive youth at higher cardiovascular risk (hypertension, diabetes, cigarette 
smoking). Screening earlier may be appropriate for patients and their primary care physicians to 
discuss lifestyle changes (e.g., diet modification, exercise regimen) and manage cholesterol 
levels. If lifestyle changes are unachievable or ineffective, earlier screening will help health care 
providers assess patients’ willingness to initiate treatment with cholesterol medications (e.g., 
statins). Strategies to promote adherence to such medications among YLH warrants further 
research.   
Screening for the full lipid profile is performed in the U.S. to measure the total 
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides in the blood.10,36 The total 
cholesterol and HDL are the only two lipids required for predicting cardiovascular risk,10 
although use of Framingham Risk Score is not validated in patients with HIV.37 Some studies 
found that the Framingham multivariable risk algorithm underestimated the presence of 
subclinical atherosclerosis (i.e. the buildup of plaque in the blood vessels) in patients with HIV, 
over-predicted rates in patients who did not receive ART, and under-predicated rates in patients 
on ART. 37,38 These findings highlight the need to incorporate ART into cardiovascular risk 
equations in HIV-positive populations.  
This study has some limitations. The study design was cross-sectional so no causality 
could be inferred. Because cholesterol data were not provided by four sites, our analytical sample 
was limited to predominately Black YLH, impacting the generalizability of our results. Since the 
code was originally written for baseline dataset, we used earliest visit data for coding HIV 
medications, which may lead to misclassification of drugs. Future studies should seek to 
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combine all medical visits to more accurately assess the scope of medication use and any 
differences between medical visits. This would be beneficial for evaluating trends in STRs 
prescribed and duration of STRs used among YLH. With the U.S. pharmaceutical drug net 
spending USD 324 billion in 2017,39 our findings can be used to examine trends in prices among 
most commonly prescribed STRs to address concerns related to costs and health policy in the 
U.S. Individual ART agents might differ in their contributions to the risk of lipid abnormalities. 
Therefore, instead of examining a class effect, understanding which type of ART contributes to 
the increased risk of lipid abnormalities would be incredibly valuable. Finally, although 
regression was used for adjusting confounders, residual confounders cannot be avoided and it 
can bias the association in any direction (towards or away from the null). Despite these 
limitations, our findings show that it is feasible to leverage EHRs to examine chronic disease 
risks in YLH and highlight the need to monitor HIV treatment in the context of overall health 
even in a young HIV-positive population.  
The present study indicates that VL non-suppression is positively and independently 
associated with lipid abnormalities in YLH, while STR was observed to be protective against 
lipid abnormalities, and these observations supplement the existing knowledge on the 
relationship among VL, STR, and lipid outcomes. In HIV-positive individuals, both the infection 
itself and its treatment with ART may contribute to an increased risk of CVD by altering blood 
lipid levels, inducing inflammation, and impacting blood-clotting processes, all of which can 
enhance CVD risk. With more effective and widespread use of STR among YLH, the impact of 
ART agents on lipid profiles must be analyzed carefully and it is important to implement more 
integrated care for this population. Because there is such a lack of knowledge on CVD, HIV, and 
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Table 1. Data Sources 
City n  % 
Baltimore 72 18.1 
Birmingham 44 11.1 
Los Angeles 67 16.8 
Memphis 157 39.4 
Tampa 54 13.6 
Washington DC 4 1.0 







Table 2. Components of Single Tablet Regimen 
Brand 
Name Components HIV Drug Category 
Atripla 600 mg efavirenz Non-nucleoside reverse transcriptase inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
300 mg tenofovir disoproxil fumarate Nucleoside reverse transcriptase inhibitor 
Complera 25 mg rilpivirine Non-nucleoside reverse transcriptase inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
300 mg tenofovir disoproxil fumarate Nucleoside reverse transcriptase inhibitor 
Delstrigo 100 mg doravirine Non-nucleoside reverse transcriptase inhibitor 
300 mg lamivudine Nucleoside reverse transcriptase inhibitor 
300 mg tenofovir disoproxil fumarate Nucleoside reverse transcriptase inhibitor 
Genvoya 150 mg elvitegravir Integrase inhibitor 
150 mg cobicistat CYP3A inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
10 mg tenofovir alafenamide Nucleoside reverse transcriptase inhibitor 
Odefsey 25 mg rilpivirine Non-nucleoside reverse transcriptase inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
25 mg tenofovir alafenadmide Nucleoside reverse transcriptase inhibitor 
Stribild 50 mg elvitegravir Integrase inhibitor 
150 mg cobicistat CYP3A inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
300 mg tenofovir disoproxil fumarate Nucleoside reverse transcriptase inhibitor 
Symtuza 800 mg darunavir Protease inhibitor 
150 mg cobicistat CYP3A inhibitor 
200 mg emtricitabine Nucleoside reverse transcriptase inhibitor 
10 mg tenofovir alafenamide Nucleoside reverse transcriptase inhibitor 
Triumeq 50 mg dolutegravir Integrase inhibitor 
600 mg abacavir Nucleoside reverse transcriptase inhibitor 
300 mg lamivudine Nucleoside reverse transcriptase inhibitor 
Sources: AIDSinfo last reviewed June 24, 2019 FDA-approved medicines fact sheet; Truong et al. (2015) Once-








Table 3. Demographic and Clinical Characteristics of the Sample (N = 398) 
  n %  
Race/Ethnicity (n = 397)    
Black 305 76.8  
Latino 23 5.8  
White 27 6.8  
Other 42 10.6  
Gender     
Male 277 69.6  
Female 121 30.4  
Viral Load (n = 394)    
Detectable VL 175 44.4  
Undetectable VL 219 55.6  
CD4 Cell Count (n = 343)    
Baseline count ≤ 200 25 7.3  
Baseline count > 200 318 92.7  
Substance Abuse Diagnosis    
Diagnosed with substance abuse 62 15.6  
Not diagnosed with substance abuse 336 84.4  
Cigarette Smoking    
Current smoking 107 26.9  
Non-smoking 291 73.1  
ART Status    
Currently on ART 367 92.2  
Not reportedly on ART  31 7.8  
ART Prescribed Categories (n = 367)    
NRTI  13 3.5  
NNRTI  8 2.2  
PI  64 17.4  
STR  352 95.9  
II  81 22.1  
Type of ART Prescribed     
One 246 67.0  
Two 95 25.9  
Three 22 6  
Four 4 1.1  
Lipid Profile    
High Total Cholesterol 60 15.1  
High LDL Cholesterol (n = 397) 113 28.5  
Hypertriglyceridemia (n = 395) 61 15.4  
Low HDL Cholesterol 162 40.7      
 M SD  
Age (Range: 14 - 26; Mdn. = 21) 21 2.7  
BMI (Range: 4.8 - 69.5; Mdn. = 23.5) 26 7.1  
Systolic BP (Range: 92 - 180; Mdn. = 130)  129 11.7  
ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse 
transcriptase inhibitor; PI, protease inhibitor; STR, single tablet regimen; II, integrase inhibitor 
LDL, low-density lipoproteins; HDL, high-density lipoproteins; BMI, body mass index; BP, blood pressure 
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Table 4. Bivariate Analysis by Lipid Profile 
 
  High Total Cholesterol   High LDL Cholesterol  Low HDL Cholesterol  Hypertriglyceridemia 
 n = 60 Test Statistics  n = 113 Test Statistics  n = 162 Test Statistics  n = 61 Test Statistics 
  n % df χ²  n % df χ²  n % df χ²  n % df χ² 
Race/Ethnicity                     
Black 43 72.9 3 1.424  84 75.0 3 1.977  127 78.4 3 1.388  34 55.7 3 19.488*** 
Latino 4 6.8    8 7.1    7 4.3    6 9.8   
White 6 10.2    10 8.9    12 7.4    10 16.4   
Other 6 10.2    10 8.9    16 9.9    11 18.0   
Gender                     
Male 43 71.7 1 0.143  81 71.7 1 0.348  95 58.6 1 15.499***  53 86.9 1 10.419*** 
Female 17 28.3    32 28.3    67 41.4    8 13.1   
Viral Load                     
Detectable VL 23 39.0 1 0.830  49 43.8 1 0.039  89 54.9 1 12.338***  24 39.3 1 0.704 
Undetectable VL 36 61.0    63 56.3    73 45.1    37 60.7   
CD4 Cell Count                     
Baseline count ≤ 200 5 10.2 1 0.719  8 8.3 1 0.215  17 12.4 1 8.850**  6 11.3 1 2.066 
Baseline count > 200 44 89.8    88 91.7    120 87.6    47 88.7   
Substance Abuse Diagnosis                    
Diagnosed  6 10.0 1 1.671  17 15.0 1 0.039  25 15.4 1 0.004  8 13.1 1 0.363 
Not diagnosed  54 90.0    96 85.0    137 84.6    53 86.9   
Cigarette Smoking                    
Current smoking 16 26.7 1 0.002  36 31.9 1 2.147  46 28.4 1 0.317  19 31.1 1 0.602 
Non-smoking 44 73.3    77 68.1    116 71.6    42 68.9   
ART Status                    
Currently on ART 55 91.7 1 0.029  100 88.5 1 2.997  152 93.8 1 0.993  56 91.8 1 0.012 
Not reportedly on ART  5 8.3    13 11.5    10 6.2    5 8.2   
ART Prescribed Categories                    
NRTI  3 5.5 1 0.692  2 2.0 1 0.967  3 2.0 1 1.868  2 3.6 1 0.000 
NNRTI  3 5.5 1 3.254  3 3.0 1 0.427  3 2.0 1 0.052  2 3.6 1 0.581 
PI  18 32.7 1 10.503***  23 23.0 1 3.233  30 19.7 1 0.952  14 25.0 1 2.513 
STR  50 90.9 1 4.132*  94 94.0 1 1.266  143 94.1 1 2.226  52 92.9 1 1.530 
II  16 29.1 1 1.854  26 26.0 1 1.195  43 28.3 1 5.834*  13 23.2 1 0.035 
                    
100 
 
 M SD df F  M SD df F  M SD df F  M SD df F 
Age  20 2.9 396 2.138**  21 2.7 395 1.139  21 2.8 396 1.376  21 2.8 393 0.675 
BMI 26 7.9 396 0.058  27 7.4 395 0.497*  27 7.9 396 19.277***  28 6.7 393 0.448* 
Systolic BP 130 11.4 396 0.096   130 11.5 395 0.120   130 11.6 396 0.129   130 10.6 393 1.518 
Note: *p < 0.05. ** p < 0.01. ***p < 0.001. 
ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; STR, single tablet 
regimen; II, integrase inhibitor 
LDL, low-density lipoproteins; HDL, high-density lipoproteins; BMI, body mass index; BP, blood pressure 
 
  
Table 5. Multivariable Logistic Regression by High Total Cholesterol† 
  
Model 1A: High Total 
Cholesterol with STR   
Model 1B: High Total Cholesterol 
with VL  
Model 1C: High Total Cholesterol 
with STR and VL 
  B 95% CI AOR   B 95% CI AOR   B 95% CI AOR 
Age -0.19 (0.71, 0.96) 0.824*  -0.21 (0.71, 0.94) 0.815**  -0.23 (0.68, 0.93) 0.794** 
Race/Ethnicity (Ref: White)            
Black -0.60 (0.16, 1.86) 0.55  -0.53 (0.19, 1.76) 0.59  -0.57 (0.16, 1.95) 0.56 
Latino -0.99 (0.03, 4.23) 0.37  -1.05 (0.03, 3.59) 0.35  -0.93 (0.03, 4.51) 0.40 
Other -0.02 (0.22, 4.33) 0.98  -0.35 (0.18, 2.84) 0.71  -0.04 (0.21, 4.35) 0.97 
Male (Ref: Female) -0.12 (0.38, 2.08) 0.89  0.12 (0.50, 2.52) 1.13  0.021 (0.43, 2.45) 1.02 
BMI 0.02 (0.97, 1.07) 1.02  0.02 ((0.97, 1.07) 1.02  0.02 (0.97, 1.08) 1.02 
Systolic BP 0.02 (0.98, 1.05) 1.02  0.01 (0.98, 1.04) 1.01  0.02 (0.99, 1.06) 1.02 
Detectable VL (Ref: Undetectable VL) --- --- ---  -0.44 (0.33, 1.28) 0.65  -0.50 (0.29, 1.27) 0.61 
CD4 Cell Count ≤ 200 (Ref: CD4 cell count > 200) 0.27 (0.40, 4.30) 1.31  0.53 (0.51, 5.65) 1.70  0.51 (0.48, 5.78) 1.67 
Diagnosed with Substance Abuse (Ref: Not diagnosed) -0.26 (0.23, 2.15) 0.77  -0.24 (0.29, 2.11) 0.79  -0.25 (0.27, 2.23) 0.78 
Current Cigarette Smoking (Ref: Non-smoking) 0.28 (0.51, 3.42) 1.33  0.40 (0.62, 3.61) 1.49  0.44 (0.58, 4.13) 1.55 
STR Prescribed (Ref: STR not prescribed) -1.83 (0.04, 0.65) 0.16*   --- --- ---   -1.98 (0.03, 0.59) 0.14** 
Note: *p < 0.05. ** p < 0.01. ***p < 0.001. 
†Dependent variable reference group: Normal Total Cholesterol 
BMI, body mass index; BP, blood pressure; STR, single tablet regimen 
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Table 6. Multivariable Logistic Regression by Low HDL Cholesterol† 
  
Model 2A: Low HDL Cholesterol 
with STR   
Model 2B: Low HDL Cholesterol 
with VL  
Model 2C: Low HDL Cholesterol 
with STR and VL 
  B 95% CI AOR   B 95% CI AOR   B 95% CI AOR 
Age -0.03 (0.88, 1.08) 0.97  -0.01 (0.89, 1.10) 1.00  -0.02 (0.89, 1.09) 0.99 
Race/Ethnicity (Ref: White)            
Black -0.42 (0.25, 1.77) 0.66  -0.59 (0.22, 1.37) 0.55  -0.45 (0.24, 1.69) 0.64 
Latino -1.22 (0.05, 1.59) 0.30  -1.59 (0.04, 1.05) 0.20  -1.27 (0.05, 1.57) 0.28 
Other -0.14 (0.26, 2.95) 0.87  -0.32 (0.23, 2.27) 0.73  -0.08 (0.27, 3.14) 0.93 
Male (Ref: Female) -1.23 (0.16, 0.54) 0.29***  -1.21 (0.16, 0.54) 0.30***  -1.23 (0.15, 0.53) 0.28*** 
BMI 0.02 (0.98, 1.05) 1.02  0.03 (0.99, 1.07) 1.03  0.02 (0.98, 1.06) 1.02 
Systolic BP 0.03 (1.01, 1.06) 1.03*  0.03 (1.00, 1.05) 1.03*  0.03 (1.00, 1.05) 1.03* 
Detectable VL (Ref: Undetectable VL) --- ---   0.68 (1.21, 3.21) 1.97**  0.73 (1.24, 3.47) 2.07** 
CD4 Cell Count ≤ 200 (Ref: CD4 cell count > 200) 1.48 (1.59, 12.06) 4.39**  1.21 (1.27, 8.77) 3.34*  1.20 (1.19, 9.35) 3.33* 
Diagnosed with Substance Abuse (Ref: Not diagnosed) 0.08 (0.54, 2.18) 1.08  0.09 (0.56, 2.13) 1.09  0.11 (0.55, 2.23) 1.12 
Current Cigarette Smoking (Ref: Non-smoking) 0.12 (0.57, 2.20) 1.12  0.01 (0.53, 1.89) 1.01  -0.05 (0.48, 1.92) 0.95 
STR Prescribed (Ref: STR not prescribed) -1.84 (0.03, 0.83) 0.16*   --- --- ---   -1.79 (0.03, 0.88) 0.17* 
Note: *p < 0.05. ** p < 0.01. ***p < 0.001. 
†Dependent variable reference group: Normal HDL Cholesterol 






CHAPTER 5 – CONCLUSION 
 The three studies included in this dissertation were designed to examine the association 
of HIV biomarkers with cardiovascular risk (Chapter 2: AIM 1), prevalence of cigarette smoking 
and metabolic syndrome and their role in viral load (VL) non-suppression (Chapter 3: AIM 2), 
and the association between single tablet regimen (STR) and lipid abnormalities (Chapter 4: 
AIM 3) among youth living with HIV (YLH).  Using de-identified electronic health records 
(EHR) data extraction of YLH aged 14-26 receiving HIV medical care at 10 clinics participating 
in the United States (U.S.) National Institutes of Health (NIH)-sponsored Adolescent Medicine 
Trials Network for HIV/AIDS Interventions (ATN) Program – Scale It Up,1 we were able to 
analyze the 2016 baseline data. Scale It Up is a network of research teams who are developing, 
testing, and brining to practice self-management interventions that positively impact the youth 
HIV prevention and care cascades. The ATN 154 Cascade Monitoring2 protocol team receives 
extracted EHR data files annually for 5 years from the 10 clinical care sites. These sites include 
Baltimore, Birmingham, Brooklyn, Los Angeles, Memphis, Miami, Philadelphia, San Diego, 
Tampa, and Washington DC.  
 We merged specific variables of interest from the baseline data files into a single 
analytic dataset of 1093 sample size for this dissertation. Because Brooklyn, Miami, and 
Philadelphia did not provide gender and systolic blood pressure data, these three sites were 
excluded from our analyses. Out of full sample, we developed two analytic samples based on 
Cardiac Risk Score1 (n =813) and Cardiac Risk Score2 (n = 398) to address AIM 1. We used the 
second analytic sample size of 398 to address AIM 2 and AIM 3. We used descriptive statistics, 
chi-square, ANOVA and independent t tests, and a series of multivariable linear regression 
models to examine the association of detectable VL and CD4 cell count ≤ 200 with 
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cardiovascular risk among YLH. We then examined the association of cigarette smoking and 
metabolic syndrome with VL by performing descriptive statistics, chi-square, ANOVA and 
independent t tests, and a series of multivariable logistic regression models. Finally, we 
examined the association of detectable VL and STR with lipid abnormalities by performing 
descriptive statistics, chi-square, ANOVA and independent t tests, and a series of multivariable 
logistic regression models. There were several important findings in this dissertation. This final 
chapter will summarize key findings from these three studies, discuss clinical and public health 
implications,  and provide recommendations for future direction.   
Key Findings and Implications 
Overall, the findings from this dissertation demonstrates an emerging theme that a 
relationship exists between detectable VL and increased risk of cardiovascular disease (CVD); 
and it appears that smoking is associated with VL non-suppression, which then is associated with 
an increased odds of having lipid abnormalities whereas STR is protective against lipid 
abnormalities in YLH in the U.S. The sample was predominantly Black and male with a little 
more than half (52.2%) having an undetectable VL. Despite using the clinic-based sample, the 
estimated proportion achieving viral suppression is low. More work is needed to reach the Joint 
United Nations Program on 90-90-90 HIV treatment targets by 2020.3 The use of traditional 
treatment methods for engagement and retention to care may not be well-suited for YLH.  
Chapter 2 
  In Chapter 2, we examined the association of detectable VL and low CD4 cell count with 
cardiovascular risk in YLH. Our findings support the hypothesis that YLH with detectable VL 
are at increased risk of CVD compared to those with undetectable VL as measured by cardiac 
risk scores. After adjusting for demographic and clinical covariates, we found that for a 1-unit 
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increase in VL, there is a 0.038 increase in log-likelihood of having CVD risk as measured by 
Cardiac Risk Score2. Upon combining VL and CD4 results together plus demographic and 
clinical covariates, we found significant positive association between VL and CVD risk as 
measured by Cardiac Risk Score2. We observed similar findings between VL and CVD risk as 
measured by Cardiac Risk Score1. However, CD4 cell count was not found to be significantly 
associated with increased risk of CVD. The findings demonstrate the independent contribution of 
detectable VL on CVD and highlight the importance of VL monitoring and promoting self-
management. Youth are less adherent to their HIV medication, less likely to see health care 
providers or maintain medical appointment, less adherent to lifestyle changes. Any youth 
oriented tool which could be utilized by youth to communicate risk to self and health care 
provider would improve awareness and has the potential to maintain viral suppression.   
 Although a number of multivariate risk models and calculators have been developed over 
the years, health care providers do not routinely use these tools as part of the standard CVD risk 
assessment unless patients have a strong family history of premature CVD in multiple relatives.4 
The Framingham general CVD risk score (2008) was shown to have reliable predictive ability4-6 
and has been commonly applied in clinical practice. This approach, however, does not consider 
lifetime risk and current guidelines recommend CVD risk assessment based on patient-specific 
characteristics (e.g., age, gender, ethnicity).4 As such, we adapted the Framingham model to 
develop two types of Cardiac Risk Scores and all patients with enough data to calculate risk were 
assumed to be 21. With the elimination of age as a limiting factor from the algorithm and 
development of Cardiac Risk Score1 (defined as the risk score for patients with systolic blood 
pressure, smoking, diabetes, and anti-hypertensive medication use) and Cardiac Risk Score2 
(defined as the risk score for patients with systolic blood pressure, smoking, diabetes, anti-
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hypertensive medication use, total cholesterol, and HDL), this study may lead to implementation 
of clinical guidelines for CVD risk assessment, especially in adolescents and young adults with 
HIV.  
There is clearly a need for accurate CVD risk assessment in this important sub-group as 
all of the risk models are highly driven by age and none of the currently available CVD risk 
scores account for an individual’s HIV status, which can significantly impact the accuracy of 
estimated CVD risk for YLH. In addition, we constructed a continuous variable as opposed to 
using a categorical score to calculate overall risk and looked at many different risk factors of 
CVD to avoid limiting to only those with overall higher risk and underestimate CVD risk for 
YLH. Prior to now, the ability of the currently available methods for risk estimation in this age 
range was unknown. Our results are among the first to examine these methods in estimating risk 
in adolescents and young adults with HIV.    
Chapter 3 
In Chapter 3, we examined the association of cigarette smoking and metabolic syndrome 
with VL in YLH. Our findings support the hypothesis that those who are smokers are more likely 
to have high plasma VL and that the presence of the components of metabolic syndrome was not 
found to be associated with the increased risk of VL non-suppression. We found that being a 
smoker significantly increased the odds of having VL non-suppression even after adjusting for 
demographic and clinical covariates and including metabolic syndrome in the model. On the 
other hand, no statistically significant differences were found when examining the association 
between ≥ 3 components of metabolic syndrome and odds of having VL non-suppression 
adjusting for demographic and clinical covariates, and as such, we could not reject the null 
hypothesis. Our study had a lower prevalence of cigarette smoking than previously reported two 
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ATN cohort studies among YLH (32.9-38.7%).7 Prevalence estimates for the metabolic 
syndrome may vary based on the criteria used; nevertheless, our study found a higher prevalence 
of metabolic syndrome compared to a more recent study of 80 HIV-positive adolescents (aged 
14.6-18y, 10%).8  
 Prior research focused on metabolic syndrome as an outcome variable and cigarette 
smoking as an independent exposure variable. However, there is mixed findings about metabolic 
syndrome and their potential association with cigarette smoking.9-11 One study used ATN data to 
look at the effect of tobacco smoking on metabolic syndrome but the findings were not 
significant.7 We wanted to test the hypothesis on a combined relationship of smoking and 
metabolic syndrome since our target population is youth with HIV. For example, a young patient 
with HIV and having a diagnosis of metabolic syndrome (e.g., with high blood sugar, high blood 
pressure, unhealthy cholesterol levels, taking medications for all of these three conditions) and 
tobacco use may be at a greater risk to have detectable VL.  Our findings supplement the existing 
knowledge on the relationship among smoking, metabolic syndrome, and VL.  
 Existing data suggest that increased cardiovascular risk in HIV-positive patients may be 
associated with abnormal fat redistribution with lipoatrophy known as lipodystrophy syndrome, 
and may not have overt obesity but it is often significantly associated with metabolic 
syndrome.12 When a study compared the CVD risk estimates in 91 HIV-positive and HIV-
negative patients from the Framingham Offspring Study who were matched for age, gender, and 
body mass index (BMI), the risk estimates were significantly higher in HIV-positive patients 
with evidence of fat redistribution.13 Consistent with our first study, having a detectable VL 
significantly increased the odds of being a cigarette smoker. Many of the demographic and 
clinical characteristics had significant associations with cigarette smoking (i.e., for every year 
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older in age the log likelihood of the patient being a cigarette smoker increased; those who had a 
diagnosis of substance abuse significantly increased the likelihood of being a cigarette smoker 
whereas those on ART decreased the likelihood of being a cigarette smoker) in both bivariate 
and multivariable analysis. These findings demonstrate the importance of utilizing home-based 
VL monitoring device aimed at lowering the overall burden of CVD risk factors in YLH. By 
identifying YLH at the highest risk could provide the necessary means of risk estimation and 
communication in this population.  
Chapter 4 
  In Chapter 4, we examined the association of detectable VL and single tablet regimen 
and their contributions to lipid abnormalities in YLH. Our findings support the hypothesis that 
VL non-suppression is associated with increased odds of lipid abnormalities and that STR is 
found to be protective against lipid abnormalities. We found that having a detectable VL was 
associated with significantly increased odds of the patient having low HDL but no significant 
association was found with total cholesterol after adjusting for demographic and clinical 
covariates and including STR in the model. On the other hand, treatment with STR was 
associated with significantly decreased odds of the patient having low HDL cholesterol and high 
total cholesterol. STRs provide many advantages for the management of HIV, including 
improved adherence, lower health care costs, and greater patient satisfaction.14 However, these 
regimens are relatively new on the drug market and each pill is a combination of multiple agents. 
It is essential for a healthcare provider to describe each HIV regimen in more detail and discuss 
possible side effects. Each regimen consists of two or more HIV drugs from the same or different 
classes and these drugs may interact with other non-HIV medications. With youth increasingly 
using technology, having an integrated patient portal linked with the EHR might be beneficial to 
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improve health education relevant to their VL results, appointment reminders, prescription 
refills, and drug interactions.   
 Although the use of STR was found to have favorable lipid profile, some ARTs such as 
protease inhibitors may increase cholesterol, which could increase risk of CVD,12 and therefore, 
the use of single tablet regimens and their impact on lipid profiles should be assessed over time. 
However, the risks of not taking ARTs are much higher because having poorly controlled VL 
leads to far worse health overall. Our finding suggests VL monitoring to ensure VL suppression 
in YLH because suppression of HIV itself may be cardioprotective, possibly by reducing 
proinflammatory cytokines (e.g., interleukin-6) that may play a role in arterial inflammation.15,16 
Utilizing technology and promoting self-management (e.g., using home-based dried blood spot 
as a VL monitoring device) may be beneficial to achieve VL suppression and eventually reduce 
the prevalence of cardiometabolic risk factors in YLH. 
In 2017, the U.S. was reported to be spending $324 billion, an astronomical amount in 
comparison to other western and developed nations, on pharmaceutical drugs.  As spending in 
this sector continues to spiral out of control in the U.S., research in the foreseeable future needs 
to address the impact this trend will have on the cost of healthcare and the implications from the 
government on related policies; both consumers and politicians (Democratic candidates for the 
Presidency) are already beginning to have serious concerns especially on the rising cost and 
availability of these medications. One way to look at the issue is taking medication such as the 
most commonly prescribed HIV medicines, single tablet regimens (e.g., Atripla and Complera) 
which are found to have favorable lipid profile. In order to look at the causal effect of these 
drugs, future research would include conducting randomized controlled trials. However, the 
more important issues concern the availability of these medications, and whether they will be 
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affordable or not to the consumers. It is imperative that future and additional research include 
attempts to look closely at the rising trend in costs and availability with one eye on the policies 
the government is expected to introduce in order to counter these issues. 
Key Strengths  
This dissertation has several key strengths. This is the first investigation to use 
multivariable modeling to examine the independent contributions of biomarkers, behavioral 
measures and ART medications on CVD risk in a U.S. population of adolescents and young 
adults with HIV treated in routine practice. The use of multivariable models based on routinely 
available EHR data integrated into a common data model is an innovative approach to improving 
our understanding of important population health risk factors that may be modifiable in routine 
practice. EMRs provided us with the opportunity to include three innovative design features in 
this dissertation: (a) the inclusion of HIV outcomes data from clinic-based patients will lower 
costs of testing for virologic and immunologic biomarkers; (b) the inclusion of ICD-10 codes to 
identify diagnosis for cigarette smoking, diabetes, and substance abuse further identify 
differences in the subgroups. The information gained may also provide valuable insight on how 
to design future clinical trials. The results of this study will help tailor current practice guidelines 
for CVD prevention in adolescents and young adults living with HIV.  
The ATN clinics serve people from diverse ethnic and racial backgrounds. A strength of 
this dissertation is that the National Heart, Lung, and Blood Institute (NHLBI) networks provide 
a platform to study adequate numbers of patients with CVD risk factors, and serve as a vehicle 
for translational research. This investigation takes advantage of a methodologically rigorous 
design, including the use of a conceptual framework and routinely available EHR data integrated 
into a common data model. This is a major advantage over other forms of epidemiological study 
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as routinely collected data allow large cross-sectional studies to be made at little or no expense 
but may give stronger evidence. This study will provide a platform to identify the landscape of 
standards to improve our understanding of an underrepresented population health risk factors that 
may be modifiable in routine practice. It will also provide a foundation to improve 
cardiovascular health assessment practices in HIV prevention and treatment clinics nationwide. 
Another advantage is that a cross-sectional study can be conducted as the first step either before 
planning a cohort study or baselining in a cohort study.17,18 These study designs are the best way 
to determine prevalence and are useful at identifying associations that can then be more 
rigorously studied using a randomized controlled trial,19 or to design future clinical trials for 
medical product development. 
Another strength of this dissertation is its use of a sophisticated analytical model to 
examine the relationships between the independent variables and outcomes and generate 
regression models after adjustment for confounders. This investigation is innovative in that we 
constructed a single multivariable risk function tailored to YLH by integrating into the existing 
CVD prediction algorithm developed based on data obtained from the Framingham Heart Study.6 
Given that the strongest predictor of cardiovascular risk in any risk equation is age and that 
almost all multivariable risk algorithms are commonly used to assess risk of CVD events in older 
adults and general population,6,20 this is the first study to develop cardiovascular risk profile with 
age assumed to be 21 and construct Cardiac Risk Scores that estimate risk of developing CVD at 
10 years for YLH without overt CVD events. 
Limitations 
Despite significant benefits, study limitations exist. Given that the 154 ATN Cascade 
Monitoring is a nationwide study capturing data from 10 different clinics across the nation, the 
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findings of this dissertation are theoretically generalizable to YLH who reside in one of the 7 
cities (Baltimore, Birmingham, Los Angeles, Memphis, Tampa, Washington, Miami). 
Unfortunately, these are urban areas and the study cannot be generalized to YLH in rural areas of 
the U.S. EHR is beneficial as it reduces secondary data entry error when creating data files 
shared between sites and the data management team, and does not rely on youth self-report of 
health. EHRs can also be leveraged to accomplish public health objectives in surveillance and 
predictions. With the 154 ATN Cascade Monitoring being a cross-project initiative of the larger 
network trial, we were able to obtain the EHR baseline data that is specific and verified, gathered 
relatively quickly in large quantities, and hence a virtual cohort of YLH was created. Although 
clinic-based studies have uncovered important biomedical associations between HIV and HIV 
related care variables, they are limited in their ability to answer social and behavioral questions 
and to generalize to larger populations.21 Since this investigation doesn’t have a comparison 
group of HIV-negative youth, it might not be possible to draw conclusions and make broad 
policy recommendations.  
Although there are 7 ATN clinic sites participating in this dissertation, the majority of 
them are located on the Eastern part of the U.S. As a result, YLH who live in other parts of the 
U.S., mainly the Midwest, Southwest, and West, are not included in this study. As mentioned 
above, all clinics are situated in major cities. YLH living in smaller cities or in rural areas are 
also excluded. This potentially biases the sample, as YLH in non-urban areas experience 
different barriers to accessing and staying in care. For instance, those in urban areas may have 
greater access to public transportation and do not have to rely on cars or parking to visit a clinic. 
In addition, those in non-urban areas may have fewer clinics nearby, experience greater stigma 
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from their community, or receive less structural support (in the form of policy or provider 
availability) for HIV-related care. 
A possible threat to external validity of this study is the small sample sizes and missing 
data for certain sites. We addressed this issue at the outset by merging data from all 10 sites to 
increase the overall size of the dataset. Critics argue that it is difficult to derive causal 
relationships from cross-sectional analysis since this is a one-time measurement of exposure and 
outcome.17 A cross-sectional design can demonstrate associations but the study design makes it 
difficult to determine the direction of causality.22,23 Because data on each patient are recorded 
only once, it would be difficult to infer the temporal association between a risk factor and an 
outcome.24,25 While we might be able to see associations between independent contributions of 
biomarkers, behavioral measures, and ART medications on CVD risk among YLH in the U.S., 
observational studies are not intended to prove causation, and causal inferences should be 
interpreted with caution.26 Misclassification, recall, selection, and interviewer bias lead to 
systematic error in the causal inferences drawn from the analyses, which are threats to internal 
validity that produce untrue associations between exposure and outcome.26 Although we adjusted 
measure of effect using regression by adding confounders as independent variables in the model, 
it is still possilbe to have residual confounding and it can bias the effect in any direction (towards 
or away from the null).27  
Overall Conclusion and Future Directions 
As demonstrated in this dissertation, overall, the variety of biomedical and behavioral 
factors that make HIV-positive individuals more susceptible to developing CVD is compelling 
evidence to reconfigure how the two ailments are addressed. Because many of the risk factors for 
CVD, including smoking and those analyzed in our three studies, can be managed by lifestyle 
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intervention, it is important that these changes take place as early as possible, which makes youth 
and young adults living with HIV an important target group. Their future risk of CVD with and 
without intervention can be assessed with regression models to help come up with prevention 
strategies. It is therefore important to focus specifically on this population because of the greater 
opportunity to make changes to therapy and lifestyle that can lead to a better overall quality of 
life and a decrease in the rate of morbidity and mortality. Future research must develop 
prediction models for simultaneously assessing risk and providing treatment for HIV and CVD, 
especially as ART both continues to improve the life expectancy for HIV-positive individuals 
and pose a risk for developing CVD. The knowledge gained from this investigation can help 
define guidelines and polices for care providers to assess and treat CVD risk factors in YLH as 
well as potentially develop cutting edge tools for HIV-positive youth to assess cardiovascular 
risk such as a cardiovascular risk assessment tailored to HIV-positive population. Some studies 
suggest that with each year an individual on ART ages, their risk for CVD increases because of 
ART’s effect on blood cholesterol and triglycerides,28,29 this would be a possible hypothesis for 
future investigation.  
The three studies included in this dissertation demonstrate that detectable VL per se may 
lead to greater prevalence of cigarette smoking and lipid abnormalities with increased risk of 
CVD. However, we used a cross-sectional study design and these studies did not have matched 
controls. Until appropriately designed research studies examine absolute relative risk between 
HIV-positive and HIV-negative individuals, ascertained risk is still not known. CVD risk does 
not appear to rapidly increase in HIV-positive individuals with age. Earlier interventions for 
reducing modifiable risk factors, such as smoking, obesity, blood pressure, cholesterol, and 
diagnosing prediabetes, can significantly decrease the risk for CVD.30 Regular doctor visits for 
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HIV care may provide additional opportunities for counseling, monitoring, and interventions for 
modifiable CVD risk factors, more so than for general population.30 By knowing how many 
modifiable CVD risk factors and what type patients have, patients and their health care providers 
can make a customized plan of action to prevent, delay, or control these modifiable CVD risk 
factors. Risk modification would include smoking cessation, cholesterol reduction, and blood 
sugar and systolic blood pressure reduction.30  
 Historically, studies that have established associations between HIV, CVD risk factors, 
and CVD, focused on older populations that have experienced cardiovascular events, and these 
findings were then generalized back to the broader HIV-positive population. A more current 
focus on reducing health disparities among sub-populations, however, highlights the need to 
include younger age groups to whom study results will be applied31 to mitigate the chance of 
premature cardiovascular events and CVDs. This type of study design is important for 
descriptive analyses and for generating hypotheses using the cardiovascular framework to 
understand the relationship between HIV-related factors and CVD among adolescents and young 
adults with HIV or those at risk for HIV in the U.S. With the use of EHRs, we can use data from 
a large number of subjects and, unlike observational studies, is not geographically bound.32 
Future directions include creating a systematic centralized database and conducting longitudinal 
data analyses to analyze trajectories of change in the cardiovascular health-related characteristics 
over time . Using a network-based recruitment approach to identify HIV-positive and HIV-
negative youth, researchers can develop prediction models and tailored treatment options for 
YLH. The knowledge gained from these studies will facilitate dissemination and advocate for 
creating and implementing policies and guidelines.   
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Taken together, this dissertation demonstrates that a relationship exists between 
detectable VL and increased risk of CVD; and cigarette smoking may lead to VL non-
suppression, which then lead to lipid abnormalities but the mechanics are poorly understood. 
When studying the young population in any aspect, it tends to be challenging to eliminate many 
factors that may be affecting treatment methods, from related diseases, and disorders to even 
societal challenges. The targeted population YLH carries a lot of interconnected factors that act 
as a tide in the ocean against seeking them, and it requires a multidisciplinary treatment method 
to increase its effectiveness in biological, societal, and even psychological way. These factors 
that tend to be overlooked as a whole may discourage a patient from a critical stage of treatment, 
or even taking the step to begin with treatment and it may increase having secondary diseases, 
such as CVD.  
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Defined as the Cardiac 
Risk Score for patients 
with systolic blood 
pressure, cigarette, and 




Developed for study per 
guidance from D’Agostino et 
al. (2008) General 
Cardiovascular Risk Profile for 
Use in Primary Care The 
Framingham Heart Study  
Cardiac Risk 
Score2 
1 Defined as the Cardiac 
Risk Score2 for 
participants with total 
cholesterol, HDL 
cholesterol, systolic blood 
pressure, smoking, and 




Developed for study per 
guidance from D’Agostino et 
al. (2008) General 
Cardiovascular Risk Profile for 
Use in Primary Care The 
Framingham Heart Study 
Tobacco_Use 2 1=Patient is reported to 
have used tobacco if 
ICD10 diagnosis codes 
report tobacco use OR 
Site reported tobacco use 
by patient response   
0=patient is reported to not 
have used tobacco if site 
reported no tobacco use by 
patient response OR value 
is missing. 
Binary Extracted EHR data 
High Total 
Cholesterol 
3 Age 19 or younger: greater 
than or equal to 170 mg/dL 
Men age 20 or older: 
greater than 200 mg/dL 





Women age 20 or older: 




Low HDL 3 Age 19 or younger: less 
than or equal to 45 mg/dL 
Men age 20 or older: less 
than 40 mg/dL 
Women age 20 or older: 
less than 50 mg/dL 










Definition and Metrics  Type Item Source 
VL_Results 1, 2, 
3 
Viral Load values as 
reported: “copies/mL”  
• Earliest date 
reported value 
• Results that were 
reported at or 
below detection 
level were 
assumed 1 value 
below detection 
level 
Numeric Extracted EHR data 
VL_UND 1, 2, 
3 
1=Patient’s viral load 
result was below the 
detectable threshold as 
reported by site 
0=Patient’s viral load was 
above the detectable 
threshold as reported by 
site 
Binary Extracted EHR data (recoded 
into a dichotomous variable) 
CD4_Results 1 Continuous variable: 
baseline CD4 cell count 
results with absolute count. 
CD4 values as reported:  
Specifically “cells/cumm” 
for site WADC and “/uL” 
for site TAFL 
• Earliest date 
reported value 
Numeric  Extracted EHR data 
AIDS 1 1=CD4_results<=200 
0=CD4_Results>200 
Binary Extracted EHR data (recoded 






















NHLBI definition; Al-Hamad 
(2017) Metabolic syndrome in 
children and adolescents; 









DrugCode_4 3 Single tablet regimen Binary  Extracted EHR data (HIV 
medication data files classified 







Definition and Metrics Type Item Source 
Age 1, 2, 
3 
Continuous variable in 
year. Years as reported by 
site.  
Numeric Extracted EHR data 
Race/Ethnicity 1, 2, 
3 
Race as reported by site. 
Categorical variable with 
four options: Black, 
Latino, White, and Other.  
Categorica
l 
Extracted EHR data (recoded 
into 4 categories) 
Gender 1, 2, 
3 
1=Sex of patient is male 
0=Sex of patient is female 
Binary Extracted EHR data 
BMI 1, 2, 
3 
Tallest and earliest date 
reported value for height 
and highest and earliest 
date reported value for 
weight were used.  
Numeric Extracted EHR data 
ART_Meds 1, 2, 
3 
1=Patient is on HIV 
medication 
0=Patient was not 
reportedly on HIV 
Medication 
Binary  Extracted and coded EHR data 
files 






LACA= Los Angeles 
California 





SDCA= San Diego 
California 
TAFL= Tampa Florida 
WADC= Washington DC 
Character Extracted EHR data 
Substance_Abuse 1, 2, 
3 
ICD 10 codes F1010, 
F1210, F1220, F1290, 
Numeric Extracted EHR data (recoded 
into dichotomous variable) 
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F1510, F1511, F1520, 
F1590, F17200, F17210, 
F1910, and F1920 to 
identify alcohol and drug 
problems that are recorded 
in the EHR systems.  
1 = Patient is diagnosed 
with substance abuse  
0 = Patient was not 
diagnosed with substance 
abuse 
 
BP_Systolic 1, 2, 
3 
Systolic Blood pressure 
value as reported by site 
Numeric Extracted EHR data 
HTN_DRUG 1, 2, 
3 
1= patient was reported by 
site to be prescribed 
hypertension medication 
0=patient was not reported 
by site to be prescribed 
hypertension medication 
Binary  Extracted EHR data (HTN 
drugs coded)  
HTN_DRUG=1 if patient drug 







Diabetes 2 1=Patient is reported to 
have diabetes if ICD10 
diagnosis codes report 
diabetes OR blood test 
results exceed 
predetermined criteria 
0=patient is reported to not 
have diabetes if patient 
does not meet 
predetermined criteria OR 
value is missing. 
Binary Extracted EHR data  
ICD10 Diagnosis Codes: 
E10XX, E11XX or E13XX 
Patients without these ICD10 
diagnosis codes were given a 
missing value for diabetes and 









Obesity 2 Patients who were between 
20 and 24 with a BMI over 
30 would be classified as 
obese; patients who were 
between 14 and 19 with a 
BMI at or above the 95th 
percentile of children of 
the same age and sex 
would be considered to 
have obesity. 
Binary Developed for study per 
guidance from the CDC 
downloaded percentile data 
files on growth charts to 
calculate the 95th percentile 
values by sex and age.  
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Hypertension  2 Systolic blood pressure ≥ 
130 mmHg or treatment 
with anti-hypertensive 
medication 
Numeric NHLBI/NCEP III (Hamad and 
Raman 2017); IDF definition 
ages 16+ adult and pediatric 
(Hamad and Raman 2017 and 
Magge et al 2017); Jaggers et 
al 2014 
High triglycerides 2 Triglyceride ≥ 150 mg/dl Binary Hamad and Raman 2017; 
Magge et al 2017 
DrugCode_COU
NT 
3 1 means patients were only 
on one type of ART. 2 
means patients were on 
two types of ART. 3 
means patients were on 3 
types of ART. 4 means 
patients were prescribed 
on 4 types of ART. 5 
means patients were 
prescribed on 5 types of 
ART.  If data are missing 
for this variable it means 
that no drug is coded for 




Extracted EHR data  
(recoded into a categorical 
variable) 
DrugCode_1 3 Nucleoside reverse 
transcriptase inhibitor 
(NRTI) 
Binary Extracted EHR data (HIV 
medication data files classified 
and coded)  
DrugCode_2 3 Non-nucleoside reverse 
transcriptase inhibitor 
(NNRTI) 
Binary Extracted EHR data (HIV 
medication data files classified 
and coded)  
DrugCode_3 3 Protease inhibitor (PI) Binary Extracted EHR data (HIV 
medication data files classified 
and coded)  
DrugCode_5 3 Integrase inhibitor (II) Binary Extracted EHR data (HIV 
medication data files classified 
and coded)  
High LDL 
Cholesterol 
3 Age 19 or younger: greater 
than or equal to 100 mg/dL 
Men age 20 or older: 
greater than or equal to 
100 mg/dL 
Women age 20 or older: 
greater than or equal to 
100 mg/dL 
Binary NIH guidelines for children’s 
cholesterol. 
https://www.nhlbi.nih.gov/heal
th-topics/high-blood-
cholesterol 
 
 
